

Use of clopidogrel with or without aspirin in patients treated with aspirin and undergoing percutaneous coronary intervention: an international, randomised, controlled trial

Lancet, The

381, 1107-1115

DOI: [10.1016/s0140-6736\(12\)62177-1](https://doi.org/10.1016/s0140-6736(12)62177-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ubiquitin-proteasome system. Cellular and Molecular Life Sciences, 2004, 61, 1589-95.	2.4	37
2	Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cellular and Molecular Life Sciences, 2005, 62, 1063-1080.	2.4	92
3	Medical Management After Coronary Stent Implantation. JAMA - Journal of the American Medical Association, 2013, 310, 189.	3.8	84
4	New oral anticoagulants after acute coronary syndrome. Best Practice and Research in Clinical Haematology, 2013, 26, 141-150.	0.7	2
6	Balancing Antiplatelet and Anticoagulant Therapies in Patients with Cardiovascular Disease. Cardiology and Therapy, 2013, 2, 85-96.	1.1	2
7	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, The, 2013, 382, 614-623.	6.3	740
8	Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?. Internal and Emergency Medicine, 2013, 8, 673-680.	1.0	10
9	Antithrombotic Therapy for Patients With Atrial Fibrillation and Atherothrombotic Vascular Disease. Circulation, 2013, 128, 684-686.	1.6	6
10	Questions and Answers on Proper Peri-Operative Management of Antiplatelet Therapy After Coronary Stent Implantation to Prevent Stent Thrombosis. American Journal of Cardiology, 2013, 112, 1046-1050.	0.7	4
11	Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2013, 170, 215-220.	0.8	55
12	Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial. American Heart Journal, 2013, 166, 669-675.	1.2	19
13	Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. American Heart Journal, 2013, 166, 864-870.	1.2	46
14	Recurrent intraventricular thrombus six months after ST-elevation myocardial infarction in a diabetic man: a case report. BMC Research Notes, 2013, 6, 348.	0.6	3
18	Acute Management of ST-Elevation Myocardial Infarction Patients Taking Dabigatran. Canadian Journal of Cardiology, 2013, 29, 1531.e13-1531.e14.	0.8	3
19	The Clinical Outcomes of Percutaneous Coronary Intervention Performed Without Pre-Procedural Aspirin. Journal of the American College of Cardiology, 2013, 62, 2083-2089.	1.2	15
21	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 1029-1049.	0.6	4
22	Clinical review: Bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management. Critical Care, 2013, 17, 239.	2.5	11
23	Antiplatelet therapy and anticoagulants. Lancet, The, 2013, 382, 24-25.	6.3	9

#	ARTICLE	IF	CITATIONS
24	Triple Antiplatelet Therapy and Combinations with Oral Anticoagulants After Stent Implantation. <i>Interventional Cardiology Clinics</i> , 2013, 2, 595-606.	0.2	0
25	Combination Antithrombotic Management for Non-“ST Segment Elevation Acute Coronary Syndromes. <i>Interventional Cardiology Clinics</i> , 2013, 2, 553-571.	0.2	0
26	New antiplatelet agents for cardiovascular disease. <i>Cmaj</i> , 2013, 185, 1405-1411.	0.9	10
27	Antiplatelet therapy and anticoagulants – Authors' reply. <i>Lancet, The</i> , 2013, 382, 25.	6.3	3
29	Antiplatelet therapy and anticoagulants. <i>Lancet, The</i> , 2013, 382, 24.	6.3	8
30	Cardiac Critical Care After Transcatheter Aortic Valve Replacement. <i>Cardiology Clinics</i> , 2013, 31, 607-618.	0.9	8
31	The Year in Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1131-1143.	1.2	22
32	Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2060-2066.	1.2	225
33	Antithrombotic therapy for PCI – getting the balance right. <i>Nature Reviews Cardiology</i> , 2013, 10, 179-179.	6.1	0
34	Antithrombotic Treatment in Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2349-2359.	1.2	151
35	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1617-1633.	0.8	81
36	Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Review. <i>Current Cardiology Reports</i> , 2013, 15, 378.	1.3	1
37	Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013. <i>Future Cardiology</i> , 2013, 9, 371-385.	0.5	0
38	Antithrombotic Regimens in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 990-991.	1.2	1
39	Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. <i>Clinical Research in Cardiology</i> , 2013, 102, 799-806.	1.5	23
40	Dual or single antiplatelet therapy with anticoagulation?. <i>Lancet, The</i> , 2013, 381, 1080-1081.	6.3	12
41	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2013, 29, S60-S70.	0.8	11
42	Oral Anticoagulation and Antiplatelets in Atrial Fibrillation Patients After Myocardial Infarction and Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2013, 62, 981-989.	1.2	313

#	ARTICLE	IF	CITATIONS
43	Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 1526-1532.	0.7	19
44	Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel?. <i>Cardiology</i> , 2013, 126, 233-243.	0.6	11
45	Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 721-728.	1.6	132
46	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915
47	Novel approaches for prevention of stroke related to transcatheter aortic valve implantation. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1311-1320.	0.6	8
49	Antiplatelet therapy strategies after percutaneous coronary intervention in patients needing oral anticoagulation. <i>Future Cardiology</i> , 2013, 9, 759-762.	0.5	0
50	Triple Antithrombotic Therapy Is the Independent Predictor for the Occurrence of Major Bleeding Complications. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 444-451.	1.4	17
51	Improved Outcomes in Cardiogenic Shock. <i>MD Conference Express</i> , 2013, 13, 6-7.	0.0	0
52	Do Ingredients Make the Difference?. <i>Circulation</i> , 2013, 127, 566-568.	1.6	2
53	Antithrombotic Therapy During and After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2058-2061.	1.6	4
54	Acute right ventricular failure caused by concomitant coronary and pulmonary embolism: successful treatment with endovascular coronary and pulmonary thrombectomy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 131-136.	0.4	15
55	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting. <i>Clinical Cardiology</i> , 2013, 36, 585-594.	0.7	16
56	Ticagrelor for acute coronary syndromes. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1473-1484.	0.6	3
57	Research Highlights: Highlights from the latest articles in antithrombotic and myocardial revascularization strategies in coronary artery disease. <i>Interventional Cardiology</i> , 2013, 5, 253-255.	0.0	0
58	Minimizing complications following stent implantation: outcomes and follow-up. <i>Interventional Cardiology</i> , 2013, 5, 301-317.	0.0	3
59	High platelet reactivity – the challenge of prolonged anticoagulation therapy after ACS. <i>Thrombosis and Haemostasis</i> , 2013, 109, 799-807.	1.8	5
60	Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 560-568.	1.8	41
61	Advances in coronary stent technology: current expectations and new developments. <i>Research Reports in Clinical Cardiology</i> , 0, , 85.	0.2	7

#	ARTICLE	IF	CITATIONS
62	Balancing between bleeding and thromboembolism after percutaneous coronary intervention in patients with atrial fibrillation. Could triple anticoagulant therapy be a solution?. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 3, 234-240.	0.1	8
63	s New oral anticoagulants “ will they be used with antiplatelet drugs in patients with atrial fibrillation after acute coronary syndrome?. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 4, 348-352.	0.1	1
64	Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy. <i>Thrombosis and Haemostasis</i> , 2013, 110, 623-625.	1.8	11
65	Antithrombotic therapy “ predictor of early and long-term bleeding complications after transcatheter aortic valve implantation. <i>Archives of Medical Science</i> , 2013, 6, 1062-1070.	0.4	21
66	Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. <i>Vascular Health and Risk Management</i> , 2014, 10, 291.	1.0	1
67	Impact of Platelet Transfusion on Survival of Patients with Intracerebral Hemorrhage after Administration of Anti-Platelet Agents at a Tertiary Emergency Center. <i>PLoS ONE</i> , 2014, 9, e97328.	1.1	24
68	Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 885.	0.9	1
69	Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. <i>Medical Journal of Australia</i> , 2014, 201, S100-5.	0.8	1
70	Eight challenges faced by general practitioners caring for patients after an acute coronary syndrome. <i>Medical Journal of Australia</i> , 2014, 201, S110-4.	0.8	1
71	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2014, 16, C2-C28.	0.0	2
73	Concurrent pulmonary thrombosis with systemic embolism: a case report. <i>Journal of Zhejiang University: Science B</i> , 2014, 15, 838-844.	1.3	2
74	Stroke After Transcatheter Aortic Valve Replacement: Incidence, Risk Factors, Prognosis, and Preventive Strategies. <i>Clinical Cardiology</i> , 2014, 37, 756-764.	0.7	69
78	Left Atrial Appendage Occlusion Addresses the Tremendous Unmet Needs of Stroke Prevention in Atrial Fibrillation That Persist Despite Recent Advances in Anticoagulation Therapy. <i>Circulation</i> , 2014, 130, 1516-1523.	1.6	8
79	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	0.6	2,164
80	Antithrombotics in atrial fibrillation and coronary disease. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 977-986.	0.6	5
81	Contemporary anticoagulation therapy in patients undergoing percutaneous intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 451-461.	0.6	1
82	One-Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the <sc>AFCAS</sc> Registry. <i>Clinical Cardiology</i> , 2014, 37, 357-364.	0.7	85
83	Combined Use of Warfarin and Oral <sc>P2Y12</sc> Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 152-159.	0.7	3

#	ARTICLE	IF	CITATIONS
85	Optimizing selection of antithrombotic therapy in patients requiring PCI and long term anticoagulation. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 414-420.	0.3	1
87	Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome. <i>Cardiology</i> , 2014, 129, 224-232.	0.6	8
89	Evolving Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Results From a Survey Among <scp>US</scp> Cardiologists. <i>Clinical Cardiology</i> , 2014, 37, 103-107.	0.7	13
90	2014 AHA/ACC Guideline for the Management of Patients With Non-“ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
91	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2014, 29, 1-9.	0.8	7
92	Atrial fibrillation and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2014, 29, 595-600.	0.8	0
93	Bleeding complications in patients undergoing percutaneous coronary interventions. <i>Coronary Artery Disease</i> , 2014, 25, 247-257.	0.3	19
95	Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 207-215.	1.4	43
96	Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion. <i>Case Reports in Cardiology</i> , 2014, 2014, 1-4.	0.1	4
97	Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations. <i>Journal of Blood Medicine</i> , 2014, 5, 25.	0.7	1
98	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, e199-267.	1.6	3,471
99	Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 114, 70-78.	0.7	56
100	Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1995-2001.	0.7	26
101	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. <i>International Journal of Cardiology</i> , 2014, 174, 471-483.	0.8	20
102	Left Atrial Appendage Closure with Transcatheter-Delivered Devices. <i>Interventional Cardiology Clinics</i> , 2014, 3, 209-218.	0.2	16
103	Single antiplatelet therapy after percutaneous coronary intervention in patients allergic to aspirin. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 308-310.	0.3	5
104	Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 331-337.	1.0	4
105	Primary PCI in dabigatran-treated patient: is transradial approach and bivalirudin infusion a safe and effective therapeutic option?. <i>Internal and Emergency Medicine</i> , 2014, 9, 695-698.	1.0	0

#	ARTICLE	IF	CITATIONS
106	Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. <i>Cardiovascular Intervention and Therapeutics</i> , 2014, 29, 193-199.	1.2	13
107	Highlights of the Year in JACC 2013. <i>Journal of the American College of Cardiology</i> , 2014, 63, 570-602.	1.2	2
109	New oral anticoagulants: are coagulation units still required?. <i>Thrombosis Journal</i> , 2014, 12, 3.	0.9	6
110	Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes. <i>Drugs</i> , 2014, 74, 451-464.	4.9	9
111	Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 101-111.	1.1	42
112	Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 64-71.	1.1	2
113	Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 19-28.	1.1	17
114	Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals. <i>Netherlands Heart Journal</i> , 2014, 22, 64-69.	0.3	22
115	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, e1-e76.	1.2	3,332
116	Revascularization strategies for patients with stable coronary artery disease. <i>Journal of Internal Medicine</i> , 2014, 276, 336-351.	2.7	18
117	Commentary on late breaking trials in interventional cardiology at ESC, VIVA, TCT, AHA (Fall 2012), and ACC 2013. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 936-943.	0.7	1
118	Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2014, 113, 888-896.	0.7	9
119	Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits?. <i>American Journal of Medicine</i> , 2014, 127, 579-585.	0.6	22
120	Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 113-124.	1.4	67
121	Fatal Bleedings With Prasugrel as Part of Triple Antithrombotic Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 225-226.	0.4	1
122	Triple Antithrombotic Therapy: Risky but Sometimes Necessary. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 171-175.	0.4	3
123	Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oral anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study. <i>American Heart Journal</i> , 2014, 167, 459-465.e1.	1.2	19
124	Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 293-298.	0.7	32

#	ARTICLE	IF	CITATIONS
125	The Current and Future Role of the Novel Oral Anticoagulantsâ€”Indications Beyond Atrial Fibrillation. <i>Heart Lung and Circulation</i> , 2014, 23, 2-9.	0.2	6
126	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. <i>European Heart Journal</i> , 2014, 35, 2524-2529.	1.0	49
127	Atrial fibrillation and coronary artery disease: Resembling twins?. <i>Journal of Cardiology</i> , 2014, 63, 169-170.	0.8	8
128	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Circulation</i> , 2014, 130, 2071-2104.	1.6	1,803
129	Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response â€” The TAILOR (Thrombocytes And Individualization of ORal antiplatelet therapy in percutaneous coronary) Tj ETQq0 0 0 rgBT /Ovæillock 10æf 50 577		
130	Pharmacological Treatment of Acute Coronary Syndromes. , 2014, , .		2
131	Triple antithrombotic therapy in cardiac patients: more questions than answers. <i>European Heart Journal</i> , 2014, 35, 216-223.	1.0	32
132	The Year in Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 201-214.	1.2	14
133	â€”Real-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. <i>American Journal of Medicine</i> , 2014, 127, 519-529.e1.	0.6	144
134	Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant. <i>Circulation</i> , 2014, 129, 1577-1585.	1.6	256
135	Secondary stroke prevention. <i>Lancet Neurology</i> , The, 2014, 13, 178-194.	4.9	227
136	Atrial Fibrillation Therapy. , 2014, , .		3
137	Antiplatelet therapy after coronary stent placement in patients with atrial fibrillation. <i>Interventional Cardiology</i> , 2014, 6, 249-251.	0.0	0
138	Balancing ischaemia and bleeding risks with novel oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2014, 11, 693-703.	6.1	22
139	Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions. <i>Current Cardiology Reports</i> , 2014, 16, 548.	1.3	2
140	Atrial fibrillation: state of the art. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 692-704.	1.0	0
141	Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1081-1092.	1.1	159
142	The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties. <i>European Heart Journal</i> , 2014, 35, 2942-2949.	1.0	65

#	ARTICLE	IF	CITATIONS
143	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 585-599.	0.9	7
144	Le coronarien en fibrillation auriculaire. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2014, 2014, 19-22.	0.0	0
145	Managing Antithrombotic Therapy in Patients With Both Atrial Fibrillation and Coronary Heart Disease. <i>Clinical Therapeutics</i> , 2014, 36, 1176-1181.	1.1	8
146	New advances in the treatment of atrial fibrillation: focus on stroke prevention. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2193-2204.	0.9	4
147	Recent Changes in Practice Guidelines for Atrial Fibrillation Management. <i>Pharmacotherapy</i> , 2014, 34, 1118-1120.	1.2	0
148	Reconsidering the Necessity of Aspirin in Stable Coronary Artery Disease— <i>Journal of the American College of Cardiology</i> , 2014, 64, 1437-1440.	1.2	4
149	Endoscopic Management of Acute Peptic Ulcer Bleeding. <i>Gastroenterology Clinics of North America</i> , 2014, 43, 677-705.	1.0	5
150	Strategies to Reduce Bleeding Risk in Acute Coronary Syndromes and Percutaneous Coronary Intervention: New and Emerging Pharmacotherapeutic Considerations. <i>Pharmacotherapy</i> , 2014, 34, 973-990.	1.2	2
151	Y a-t-il des liens entre maladie veineuse thromboembolique et risque artériel ?. <i>Archives of Cardiovascular Diseases Supplements</i> , 2014, 6, 86-92.	0.0	0
152	Anticoagulation Strategies for the Management of Postoperative Atrial Fibrillation. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 537-561.	0.7	31
153	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
154	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
156	Polypharmacy in Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 577-590.	1.0	11
158	Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1270-1280.	1.2	53
159	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2014, 45, 2160-2236.	1.0	3,891
160	Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1850-1860.	1.9	9
161	Durée de la bithérapie antiplaquettaire après mise en place d'un stent actif. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2014, 2014, 15-18.	0.0	0
162	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490

#	ARTICLE	IF	CITATIONS
163	Combined anticoagulation and antiplatelet therapy in AF patients: why do we not follow guidelines?. <i>Heart</i> , 2014, 100, 1565-1566.	1.2	1
164	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
165	Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. <i>Heart and Vessels</i> , 2014, 29, 578-583.	0.5	23
167	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2246-2280.	1.2	569
168	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 233-241.	1.0	81
169	Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTEMI-ACS). <i>Cardiovascular Intervention and Therapeutics</i> , 2014, 29, 123-133.	1.2	2
170	Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs. <i>Thrombosis Journal</i> , 2014, 12, 7.	0.9	14
171	ANTICOAGULATION AND ANTIPLATELET PATTERNS IN PATIENTS WITH ATRIAL FIBRILLATION POST-PERCUTANEOUS CORONARY INTERVENTION. <i>Canadian Journal of Cardiology</i> , 2014, 30, S330.	0.8	0
172	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014, 16, 1655-1673.	0.7	105
173	Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Vascular Medicine</i> , 2014, 19, 190-204.	0.8	11
174	One Weapon, Two Blows in the War Against the Thrombus. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2699-2701.	1.2	2
176	Rationale for Left Atrial Appendage Exclusion. <i>Interventional Cardiology Clinics</i> , 2014, 3, 203-208.	0.2	0
177	Hemorragias mortales relacionadas con un tratamiento antitrombótico triple que incluye prasugrel. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 225-226.	0.6	2
178	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 64, 231-232.	1.2	0
179	Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014, 113, 936-944.	0.7	17
180	Tratamiento antitrombótico combinado triple: arriesgado pero a veces necesario. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 171-175.	0.6	8
181	The WOEST study: Critical considerations and applicability. <i>Cor Et Vasa</i> , 2014, 56, e254-e258.	0.1	9
182	Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1929-1943.	2.0	79

#	ARTICLE	IF	CITATIONS
183	Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 285-298.	1.0	8
184	Role of Novel and Emerging Oral Anticoagulants for Secondary Prevention of Acute Coronary Syndromes. <i>Pharmacotherapy</i> , 2014, 34, 590-604.	1.2	7
185	The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1080-1087.	1.8	60
186	Bare-Metal vs. Drug-Eluting Stents in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 2674-2681.	0.7	21
187	Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 924-931.	1.8	39
188	Review of the top 5 cardiology studies of 2013-14. <i>Canadian Pharmacists Journal</i> , 2015, 148, 349-354.	0.4	3
189	Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9185 Patients. <i>Clinical Cardiology</i> , 2015, 38, 499-509.	0.7	25
190	Incidence and Predictors of Left Ventricular Thrombus After Primary Percutaneous Coronary Intervention for Anterior ST-segment Elevation Myocardial Infarction. <i>Clinical Cardiology</i> , 2015, 38, 590-597.	0.7	29
191	Triple therapy for percutaneous coronary intervention in atrial fibrillation: standard of care, or a nightmare soon to end?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S332-S335.	1.9	2
192	Overview of the 79 th Annual Scientific Meeting of the Japanese Circulation Society "Late-Breaking Cardiovascular Medicine From Japan". <i>Circulation Journal</i> , 2015, 79, 1675-1679.	0.7	0
193	Effects of Dabigatran on the Resolution of Left Ventricular Thrombus after Acute Myocardial Infarction. <i>Internal Medicine</i> , 2015, 54, 1761-1763.	0.3	18
194	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	1.8	201
195	Acute myocardial infarction in the elderly. <i>Netherlands Heart Journal</i> , 2015, 23, 475-476.	0.3	0
196	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.4	57
197	Dual Antiplatelet Compared to Triple Antithrombotic Therapy in Anterior Wall Acute Myocardial Infarction Complicated by Depressed Left Ventricular Ejection Fraction. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 445-449.	0.2	6
198	Dual or triple therapy in patients with atrial fibrillation and drug-eluting stents?. <i>Coronary Artery Disease</i> , 2015, 26, 367-368.	0.3	1
199	Low On-treatment Platelet Reactivity Predicts Long-term Risk of Bleeding After Elective PCI. <i>Journal of Interventional Cardiology</i> , 2015, 28, 531-543.	0.5	3
200	Outcomes following implantation of the biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the BIO-MATRIX registry. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1151-1160.	0.7	13

#	ARTICLE	IF	CITATIONS
201	Triple therapy for atrial fibrillation and percutaneous coronary intervention. <i>Current Opinion in Cardiology</i> , 2015, 30, 690-696.	0.8	1
202	Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. <i>Coronary Artery Disease</i> , 2015, 26, 372-380.	0.3	19
203	STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. <i>Fukushima Journal of Medical Sciences</i> , 2015, 61, 79-85.	0.1	1
204	Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study. <i>Clinical Interventions in Aging</i> , 2015, 10, 515.	1.3	7
205	P2Y12 inhibitors for acute coronary syndromes: current perspectives. <i>Research Reports in Clinical Cardiology</i> , 2015, , 123.	0.2	0
206	Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. <i>World Journal of Critical Care Medicine</i> , 2015, 4, 40.	0.8	30
207	Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2015, 15, 115-119.	0.2	0
208	Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 263.	0.9	6
209	Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 704-713.	0.3	1
210	Anti-coagulation for Patients with Acute Coronary Syndrome. <i>Journal of the Japanese Coronary Association</i> , 2015, 21, 272-277.	0.0	0
211	Managing atrial fibrillation in the very elderly patient: challenges and solutions. <i>Vascular Health and Risk Management</i> , 2015, 11, 555.	1.0	47
212	Recent advances in the diagnosis and treatment of acute myocardial infarction. <i>World Journal of Cardiology</i> , 2015, 7, 243.	0.5	138
213	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. <i>International CLARIFY Registry. PLoS ONE</i> , 2015, 10, e0125164.	1.1	15
214	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2) Tj ETQq1 1 0.784314 rgBT /Over	0.7	14
215	Oral anticoagulant therapy for atrial fibrillation in patients with coronary heart disease. <i>Journal of the Japanese Coronary Association</i> , 2015, 21, 234-238.	0.0	0
216	Contemporary Antiplatelet Strategies in the Treatment of STEMI using Primary Percutaneous Coronary Intervention. <i>Interventional Cardiology Review</i> , 2015, 10, 26.	0.7	1
217	Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 819-824.	0.7	14
218	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. <i>Drugs</i> , 2015, 75, 979-998.	4.9	10

#	ARTICLE	IF	CITATIONS
219	Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. <i>Europace</i> , 2015, 17, 840-854.	0.7	28
220	Percutaneous Coronary Intervention and the Various Coronary Artery Disease Syndromes. <i>Cardiovascular Medicine</i> , 2015, , 597-620.	0.0	0
221	Risks and Benefits of Triple Oral Anti-Thrombotic Therapies After Acute Coronary Syndromes and Percutaneous Coronary Intervention. <i>Drug Safety</i> , 2015, 38, 481-491.	1.4	6
223	Triple Antithrombotic Therapy in Atrial Fibrillation Patients With an Indication for Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e003217.	1.4	1
224	Deciding on a combination of anticoagulant and antiplatelet drugs. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, 638-641.	0.2	0
225	Antithrombotic strategy variability in ATRial fibrillation and obstructive coronary disease revascularized with PCIâ€”rationale and study design of the prospective observational multicenter AVIATOR 2 registry. <i>American Heart Journal</i> , 2015, 170, 1234-1242.	1.2	4
226	Outcomes of Patients With AcuteÂMyocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant andÂDualÂAntiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1880-1889.	1.1	87
228	Current strategies for bridging dual antiplatelet therapy in patients requiring surgery. <i>Interventional Cardiology</i> , 2015, 7, 137-148.	0.0	2
229	Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 403-410.	0.2	5
230	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. <i>Indian Heart Journal</i> , 2015, 67, S13-S34.	0.2	11
231	Do Not Use Novel Antiplatelet Agents inÂPatients on Oral Anticoagulants AfterÂStenting. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1890-1892.	1.1	2
232	Managing Acute Coronary Syndromes in the Elderly. <i>The Consultant Pharmacist</i> , 2015, 30, 265-282.	0.4	6
233	Solving the Issue of Restenosis After Stenting of Intracranial Stenoses: Experience with Two Thin-Strut Drug-Eluting Stents (DES)â€”Taxus Elementâ„¢ and Resolute Integrityâ„¢. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 583-591.	0.9	16
234	Antiplatelet properties of oral anticoagulants. <i>International Journal of Cardiology</i> , 2015, 181, 413-414.	0.8	5
235	Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. <i>Clinical Pharmacokinetics</i> , 2015, 54, 147-166.	1.6	137
236	Rationale and design of MANJUSRI trial: A randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. <i>Contemporary Clinical Trials</i> , 2015, 40, 166-171.	0.8	19
237	Anticoagulation After Anterior Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 163-165.	1.1	2
238	Novedades cardiovasculares 2013/2014. <i>Revista Clinica Espanola</i> , 2015, 215, 33-42.	0.2	0

#	ARTICLE	IF	CITATIONS
239	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study. <i>International Journal of Cardiology</i> , 2015, 183, 105-110.	0.8	17
240	Triple Therapy for Atrial Fibrillation and ACS With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2015, 65, 515-516.	1.2	9
241	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 516-518.	1.2	1
243	New Approaches to Inhibiting Platelets and Coagulation. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 373-397.	4.2	44
244	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. <i>Current Treatment Options in Neurology</i> , 2015, 17, 331.	0.7	1
245	Cardiovascular news 2013/2014. <i>Revista Clínica Española</i> , 2015, 215, 33-42.	0.3	0
246	An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). <i>American Heart Journal</i> , 2015, 169, 472-478.e5.	1.2	140
247	Updates and Current Recommendations for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice. <i>American Journal of Cardiology</i> , 2015, 115, 10A-22A.	0.7	20
248	Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 115, 1185-1193.	0.7	65
249	Engaging with quality improvement in anticoagulation management. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 403-409.	1.0	16
250	Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. <i>Contemporary Clinical Trials</i> , 2015, 43, 129-132.	0.8	24
251	Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1983-1995.	0.9	12
252	Triple Therapy—Can We Replace More With Better?. <i>Journal of the American College of Cardiology</i> , 2015, 66, 628-630.	1.2	1
253	Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 616-627.	1.2	93
254	Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome. <i>Thrombosis Research</i> , 2015, 136, 243-249.	0.8	2
255	Intensive Care Unit Management of Transcatheter Aortic Valve Recipients. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2015, 19, 95-105.	0.4	4
256	Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 191-197.	1.4	15
257	Management of the patient with an acute coronary syndrome using oral anticoagulation. <i>Netherlands Heart Journal</i> , 2015, 23, 407-414.	0.3	4

#	ARTICLE	IF	CITATIONS
258	Practical experience with ticagrelor: an Australian and New Zealand perspective. <i>Current Medical Research and Opinion</i> , 2015, 31, 1469-1477.	0.9	8
259	Complex Disease, Partial Revascularization, and Adverse Outcomes in Patients Treated With Long-Term Warfarin Therapy Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 116, 350-354.	0.7	0
260	One-pot click access to triazole bridged cyclodextrin chiral phases for differentiation of clopidogrel enantiomers. <i>Analytical Methods</i> , 2015, 7, 6432-6436.	1.3	2
261	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	1.0	175
262	Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction in a Patient Taking Dabigatran for Chronic Anticoagulation. <i>Texas Heart Institute Journal</i> , 2015, 42, 158-161.	0.1	0
263	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	4
264	Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation. <i>Current Cardiology Reports</i> , 2015, 17, 41.	1.3	0
265	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. <i>Blood Reviews</i> , 2015, 29, 335-343.	2.8	24
267	Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1481-1484.	0.8	2
268	The Spectrum of Thrombin in Acute Coronary Syndromes. <i>Thrombosis Research</i> , 2015, 135, 782-787.	0.8	12
269	Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists. <i>Thrombosis Research</i> , 2015, 135, 958-962.	0.8	8
270	Effective practical management of patients with atrial fibrillation when using new oral anticoagulants. <i>Annals of Medicine</i> , 2015, 47, 278-288.	1.5	0
271	When Is a Double Better Than a TRIPLE?. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1630-1632.	1.2	19
273	Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 193-197.	1.0	14
274	Dual Pathway Therapy for Secondary Prevention Following Acute Coronary Syndrome. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
275	Primary percutaneous coronary intervention and bleeding risk in the era of drug-eluting stent: a long-term cohort study. <i>Cardiovascular Intervention and Therapeutics</i> , 2015, 30, 216-226.	1.2	5
276	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	1.2	401
277	Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. <i>Journal of Cardiology</i> , 2015, 65, 197-202.	0.8	21

#	ARTICLE	IF	CITATIONS
278	Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?. Postgraduate Medicine, 2015, 127, 396-404.	0.9	1
279	Antithrombotic Therapy and Outcomes After ICD Implantation in Patients With Atrial Fibrillation and Coronary Artery Disease: An Analysis From the National Cardiovascular Data Registry (NCDR) ^Â. Journal of the American Heart Association, 2015, 4, .	1.6	8
280	Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. International Journal of Cardiology, 2015, 191, 244-253.	0.8	25
281	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	0.7	28
282	Antiplatelet Treatment in Essential Hypertension: Where Do We Stand?. Current Hypertension Reports, 2015, 17, 536.	1.5	6
283	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet, The, 2015, 386, 303-310.	6.3	117
284	Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet, The, 2015, 386, 292-302.	6.3	59
285	Practical Management of Anticoagulation in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 1340-1360.	1.2	92
286	The Conundrum of Reducing Ischemic and Bleeding Events After PCI. Journal of the American College of Cardiology, 2015, 65, 1421-1423.	1.2	11
287	Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment. Herz, 2015, 40, 1070-1083.	0.4	18
288	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas GrÃ¼ntzig Lecture ESC 2014. European Heart Journal, 2015, 36, 3320-3331.	1.0	441
289	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. Current Cardiology Reports, 2015, 17, 64.	1.3	1
291	Optimal Stroke Prevention in the Geriatric Patient with Atrial Fibrillation: Position Paper of an Interdisciplinary Expert Panel. Drug Research, 2015, 65, 505-514.	0.7	8
292	Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and olderâ€”rationale and design of the POPular AGE study. American Heart Journal, 2015, 170, 981-985.e1.	1.2	43
293	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2015, 66, 777-787.	1.2	39
294	The Challenge of Getting it Just Right. Journal of the American College of Cardiology, 2015, 66, 788-790.	1.2	1
296	Impact of atrial fibrillation type during acute coronary syndromes: Clinical features and prognosis. Revista Portuguesa De Cardiologia, 2015, 34, 403-410.	0.2	20
297	Medical and Invasive Management of Coronary Artery Disease in Patients on Anticoagulants. , 2015, , 163-174.		0

#	ARTICLE	IF	CITATIONS
298	Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2015, 373, 2038-2047.	13.9	672
301	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1089-1090.	1.2	3
302	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1036-1045.	1.2	344
303	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
304	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2133-2147.	0.9	30
305	Controversies in Cardiology. , 2015, , .		0
306	Effect of Shenzhu Guanxin Recipe (姜枣葱豉汤) on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 408-416.	0.7	13
307	Incidence, diagnostic methods, and evolution of left ventricular thrombus in patients with anterior myocardial infarction and low left ventricular ejection fraction: a prospective multicenter study. <i>American Heart Journal</i> , 2015, 170, 256-262.	1.2	76
308	Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. <i>Thrombosis Research</i> , 2015, 135, 26-30.	0.8	58
309	Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 203-208.	1.0	13
310	Early coronary vein stenosis after cardiac resynchronization therapy. <i>Herz</i> , 2015, 40, 165-168.	0.4	1
311	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 386-386.	0.4	46
312	Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015, 12, 30-47.	6.1	299
313	Successful resolution of a left ventricular thrombus with apixaban treatment following acute myocardial infarction. <i>Heart and Vessels</i> , 2016, 31, 118-123.	0.5	40
314	Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217843.	0.2	22
315	Why we should not skip aspirin in cardiovascular prevention. <i>Hamostaseologie</i> , 2016, 36, 33-43.	0.9	14
316	Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true. <i>Rational Pharmacotherapy in Cardiology</i> , 2016, 12, 465-470.	0.3	1
317	Is Dual Antiplatelet Therapy Necessary in Transcatheter Aortic Valve Implantation?. <i>International Heart Journal</i> , 2016, 57, 129-131.	0.5	0

#	ARTICLE	IF	CITATIONS
318	ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION?. Rational Pharmacotherapy in Cardiology, 2016, 12, 191-195.	0.3	2
319	Triple troubles selecting optimal therapy for atrial fibrillation patients undergoing percutaneous coronary interventions. Postepy W Kardiologii Interwencyjnej, 2016, 4, 287-289.	0.1	0
320	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis & Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	1.8	24
321	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. Thrombosis and Haemostasis, 2016, 116, S33-S40.	1.8	8
322	Dual Antiplatelet Therapy and Anticoagulation in Patients Post Percutaenous Coronary Intervention. Archives of Medicine, 2016, 8, .	0.2	0
324	Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. PLoS ONE, 2016, 11, e0147245.	1.1	25
325	Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation. Postepy W Kardiologii Interwencyjnej, 2016, 4, 290-302.	0.1	3
326	Clinical Relevance of Anticoagulation and Dual Antiplatelet Therapy to the Outcomes of Patients With Atrial Fibrillation and Recent Percutaneous Coronary Intervention With Stent. Journal of Clinical Medicine Research, 2016, 8, 153-161.	0.6	24
327	Electrochemical Determination of Cancer and Cardiovascular Biomarkers Based on Advanced Screen-printed Immunosensors. International Journal of Electrochemical Science, 2016, , 9438-9446.	0.5	2
328	Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. Canadian Journal of Hospital Pharmacy, 2016, 69, 280-5.	0.1	4
329	Pancreatic cancer control. European Journal of Cancer Prevention, 2016, 25, 188-195.	0.6	9
330	Antiplatelet and Anticoagulation Treatment in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Cardiology in Review, 2016, 24, 170-176.	0.6	2
331	Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents. European Journal of Pharmacology, 2016, 786, 246-252.	1.7	12
332	Management of Patients With NSTEMI-ACS. Journal of the American College of Cardiology, 2016, 68, 313-321.	1.2	62
334	Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. Journal of Thrombosis and Haemostasis, 2016, 14, 273-281.	1.9	37
335	Duration of dual anti–platelet therapy following drug eluting stents. Catheterization and Cardiovascular Interventions, 2016, 87, 733-734.	0.7	0
336	Coronary artery disease in outpatients with nonvalvular atrial fibrillation. Coronary Artery Disease, 2016, 27, 497-503.	0.3	2
337	Novel oral anticoagulants in the management of coronary artery disease. Coronary Artery Disease, 2016, 27, 412-419.	0.3	4

#	ARTICLE	IF	CITATIONS
338	Complementary role of cardiac CT in the assessment of aortic valve replacement dysfunction. <i>Open Heart</i> , 2016, 3, e000494.	0.9	23
342	Anticoagulant-Related Bleeding and Mortality —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2522-2524.	1.2	13
343	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
344	Atrial Fibrillation and PCI — Do We Still Need Aspirin?. <i>New England Journal of Medicine</i> , 2016, 375, 2490-2492.	13.9	6
345	How I use anticoagulation in atrial fibrillation. <i>Blood</i> , 2016, 128, 2891-2898.	0.6	8
346	2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 893-952.	0.8	113
347	Acute coronary syndromes. <i>Clinical Medicine</i> , 2016, 16, s43-s48.	0.8	20
348	Diagnosis and management of heart disease in the elderly. , 2016, , 157-186.		0
350	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	1.2	1,232
351	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016, 39, 715-727.	1.4	12
352	Direct oral anticoagulant use and stent thrombosis following an acute coronary syndrome: A potential new pharmacological option?. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 359-369.	0.7	1
354	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 662-670.	1.5	12
355	Optimal antithrombotic treatment in patients with atrial fibrillation and coronary stents. <i>Current Opinion in Cardiology</i> , 2016, 31, 356-365.	0.8	1
356	Practice Variation in Patients Eligible for Triple Therapy. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 44-46.	1.3	0
357	Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation. <i>Journal of Cardiology</i> , 2016, 68, 517-522.	0.8	6
358	State of affairs: Design and structure-activity relationships of reversible P2Y ₁₂ receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2739-2754.	1.0	15
359	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
360	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24

#	ARTICLE	IF	CITATIONS
361	Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Progress in Cardiovascular Diseases, 2016, 58, 676-692.	1.6	78
363	Hospital readmissions after percutaneous coronary intervention are declining, but caution ahead is needed. American Heart Journal, 2016, 179, 192-194.	1.2	1
364	Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low/moderate risk of stroke?. European Journal of Internal Medicine, 2016, 35, e9-e10.	1.0	2
365	Neurological Events Following Transcatheter Aortic Valve Replacement and Their Predictors. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	79
366	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	0.8	243
367	Anticoagulation for Atrial Fibrillation in the Emergency Department or Observation Unit. Contemporary Cardiology, 2016, , 87-100.	0.0	0
368	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Journal of Thoracic and Cardiovascular Surgery, 2016, 152, 1243-1275.	0.4	249
369	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
370	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
371	Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic Proceedings, 2016, 91, 1413-1447.	1.4	10
372	Temporal Trends, Predictors, and Outcomes of In-Hospital Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 1150-1157.	0.7	23
373	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. International Journal of Cardiology, 2016, 225, 154-158.	0.8	0
374	Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. International Journal of Cardiology, 2016, 223, 186-194.	0.8	29
375	Triple Oral Antithrombotic Therapy. JAMA Internal Medicine, 2016, 176, 1433.	2.6	0
376	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. American Heart Journal, 2016, 180, 82-89.	1.2	19
377	Short Stay Management of Atrial Fibrillation. Contemporary Cardiology, 2016, , .	0.0	1
378	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
379	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523

#	ARTICLE	IF	CITATIONS
380	Design and Rationale of the <sc>REâ€œDUAL PCI</sc> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	0.7	65
381	Gastroprotection with proton-pump inhibitors in high-risk cardiovascular patients: who to target and for how long?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1451-1453.	1.0	3
382	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AFâ€œTIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	93
383	A Fresh Perspective on Atrial Fibrillation âˆ—. <i>Journal of the American College of Cardiology</i> , 2016, 68, 905-907.	1.2	0
384	Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1706-1717.	1.1	115
385	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	1.1	21
386	Anticoagulation Treatment After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1718-1720.	1.1	5
387	Reply. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2366-2368.	1.1	0
388	Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. <i>Circulation Journal</i> , 2016, 80, 354-362.	0.7	25
389	Triple Antithrombotic Therapyâ€œ Always One Too Many? â€œ. <i>Circulation Journal</i> , 2016, 80, 316-317.	0.7	1
390	Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	42
391	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016, 181, 92-100.	1.2	20
392	To neither bleed nor clot: That is the question. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 367-368.	0.7	0
394	Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1473-1483.	1.1	24
395	Updates on Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016, 1, 718.	3.0	127
396	Walking the Tightrope Between Suppressing Ischemia and Minimizing Bleeding. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1484-1486.	1.1	0
397	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 558-565.	1.0	3
399	Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. <i>New England Journal of Medicine</i> , 2016, 375, 2423-2434.	13.9	1,265

#	ARTICLE	IF	CITATIONS
400	Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 611-622.	1.3	8
401	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
402	Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	21
403	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
404	Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, S2-S12.	1.8	7
406	The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model. <i>Medicine (United States)</i> , 2016, 95, e4145.	0.4	2
407	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E12-22.	0.7	22
408	Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016, 134, e123-55.	1.6	1,069
409	Percutaneous coronary intervention for three vessels of chronic total occlusion complicated with huge left ventricular thrombus. <i>Cardiovascular Intervention and Therapeutics</i> , 2016, 31, 321-328.	1.2	0
410	Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 147-159.	2.3	55
411	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.	1.2	51
412	Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 909-919.	0.7	5
413	Practice Variation in Triple Therapy for Patients With Both Atrial Fibrillation and Coronary Artery Disease. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 36-43.	1.3	4
414	Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 592-599.e1.	0.6	49
415	Dual pathway therapy in acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 254-260.	1.0	11
416	Meta-Analysis of Oral Anticoagulants with Dual versus Single Antiplatelet Therapy in Patients after Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 103-110.	1.0	9
417	Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?. <i>International Journal of Cardiology</i> , 2016, 203, 987-994.	0.8	21
418	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <i>EBioMedicine</i> , 2016, 4, 26-39.	2.7	15

#	ARTICLE	IF	CITATIONS
419	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	1.0	8
420	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016, 174, 120-128.	1.2	29
421	Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence. <i>Clinical Therapeutics</i> , 2016, 38, 961-973.	1.1	1
422	Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry. <i>International Journal of Cardiology</i> , 2016, 212, 311-317.	0.8	8
423	Secondary Prevention of Cardioembolic Stroke. , 2016, , 1014-1029.e4.		0
425	Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 231-241.	1.0	1
426	Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. <i>American Heart Journal</i> , 2016, 173, 77-85.	1.2	64
427	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 426-436.	1.1	135
428	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 257-271.	1.0	8
429	The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy. <i>Expert Review of Hematology</i> , 2016, 9, 223-225.	1.0	6
430	Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials. <i>International Journal of Cardiology</i> , 2016, 205, 89-96.	0.8	25
431	Coronary revascularisation in older patients with non-ST elevation acute coronary syndromes. <i>Heart</i> , 2016, 102, 416-424.	1.2	14
432	Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. <i>European Heart Journal</i> , 2016, 37, 2263-2271.	1.0	235
433	A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance. <i>International Journal of Cardiology</i> , 2016, 202, 900-903.	0.8	0
434	Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments. <i>European Heart Journal</i> , 2016, 37, 1268-1283.	1.0	88
435	Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures. <i>International Journal of Cardiology</i> , 2016, 202, 578-585.	0.8	34
436	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
437	Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 93-97.	0.4	19

#	ARTICLE	IF	CITATIONS
438	Comparison of mid-term outcomes between patients with and without atrial fibrillation undergoing coronary stenting in the second-generation drug-eluting stent era: from the SHINANO registry. <i>Cardiovascular Intervention and Therapeutics</i> , 2017, 32, 206-215.	1.2	7
439	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E64-E74.	0.7	10
440	Antithrombotic Management After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 75-78.	1.1	10
443	Dabigatran-related platelet thrombin response during triple anti-thrombotic therapy: A matter of time?. <i>Thrombosis Research</i> , 2017, 149, 62-63.	0.8	0
444	Clinical characteristics of complex aortic plaque in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 230, 85-90.	0.8	3
445	Antiplatelet therapies in patients with an indication for anticoagulation. <i>Clinical Hemorheology and Microcirculation</i> , 2017, 64, 273-278.	0.9	4
446	Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. <i>European Journal of Internal Medicine</i> , 2017, 40, 1-7.	1.0	5
448	Going Polymer Free and Dual Antiplatelet Free Earlier. <i>Journal of the American College of Cardiology</i> , 2017, 69, 172-175.	1.2	7
449	Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants. <i>JAMA Cardiology</i> , 2017, 2, 442.	3.0	55
450	Percutaneous Coronary Intervention of Complex Calcified Lesions With Drug-Coated Balloon After Rotational Atherectomy. <i>Journal of Interventional Cardiology</i> , 2017, 30, 139-146.	0.5	37
454	Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 546-551.	1.0	28
456	Use of rivaroxaban in patients with stroke. <i>Neurological Sciences</i> , 2017, 38, 745-754.	0.9	1
457	Bleeding associated with the management of acute coronary syndromes. <i>Heart</i> , 2017, 103, 546-562.	1.2	5
458	Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. <i>Heart</i> , 2017, 103, 871-884.	1.2	4
459	Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e604-e633.	1.6	198
460	Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 835-847.	1.9	191
461	Safety and efficacy of anti-thrombotic regimens in patients with percutaneous coronary intervention requiring oral anticoagulation: A traditional and network meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 535-543.	0.3	3
462	A Case Series of Acute Myocardial Infarction in Left Ventricular Assist Device-Supported Patients. <i>ASAIO Journal</i> , 2017, 63, e18-e24.	0.9	5

#	ARTICLE	IF	CITATIONS
463	The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2017, 2, 713.	3.0	10
464	Triple antithrombotic therapy, including NAO, in patients after coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e125-e128.	0.6	0
465	Vessel tree tracking in angiographic sequences. <i>Journal of Medical Imaging</i> , 2017, 4, 025001.	0.8	7
466	Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 875-883.	0.9	10
467	New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2485-2487.	1.2	8
468	Riskier Business. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	0
469	Prophylactic warfarin post anterior ST-elevation myocardial infarction: A systematic review and meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 559-564.	0.3	15
471	Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Medicine</i> , 2017, 130, 1280-1289.	0.6	28
472	The future of atrial fibrillation management: integrated care and stratified therapy. <i>Lancet, The</i> , 2017, 390, 1873-1887.	6.3	128
473	Management of Atrial Fibrillation in Elderly Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 185-193.	1.3	11
474	Antithrombotic Therapy to Reduce Ischemic Events in Acute Coronary Syndromes Patients Undergoing Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017, 6, 131-140.	0.2	5
475	Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 61-70.	0.8	20
476	Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1075-1085.	1.1	43
477	Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1086-1088.	1.1	15
478	Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. <i>International Journal of Cardiology</i> , 2017, 243, 263-269.	0.8	9
479	Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017, 376, 2053-2064.	13.9	761
480	Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 588-591.	0.3	1
481	Oral Anticoagulation Therapy. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
482	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 965-976.	0.8	89
483	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. <i>American Heart Journal</i> , 2017, 190, 86-93.	1.2	19
484	Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 425-430.	0.3	11
485	Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 157-162.	1.4	16
486	Antiplatelet therapy in acute coronary syndrome. <i>Continuing Cardiology Education</i> , 2017, 3, 11-21.	0.4	1
487	The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 561-572.	1.0	21
488	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Suggested strategies tailored to an integrated evaluation of different risk profiles. <i>European Journal of Internal Medicine</i> , 2017, 41, e10-e11.	1.0	1
489	Prognostic Value of Ankle-Brachial Index in Patients Undergoing Percutaneous Coronary Intervention: In-Hospital and 1-Year Outcomes From the SHINANO Registry. <i>Angiology</i> , 2017, 68, 884-892.	0.8	7
490	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , 2017, 389, 1799-1808.	6.3	174
491	Atrial Fibrillation on Vitamin K Antagonist Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Elevation Myocardial Infarction. , 2017, , 79-94.		0
492	2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: comments from the Dutch ACS working group. <i>Netherlands Heart Journal</i> , 2017, 25, 181-185.	0.3	49
493	Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. , 2017, , 59-77.		0
494	Dual antiplatelet therapy for secondary prevention of coronary artery disease. <i>Open Heart</i> , 2017, 4, e000651.	0.9	49
495	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 616-664.	0.6	510
496	Contemporary Use of Oral Antithrombotic Agents: Focus on Dual and Triple Therapeutic Approaches. <i>Pharmacotherapy</i> , 2017, 37, 1545-1564.	1.2	0
497	Triple Therapy for Atrial Fibrillation after PCI. <i>New England Journal of Medicine</i> , 2017, 377, 1580-1582.	13.9	31
499	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2017, 38, 2739-2791.	1.0	5,142
500	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	13.9	1,099

#	ARTICLE	IF	CITATIONS
501	Safety and Efficacy of Polymer-Free Biolimus A9â€œCoated Versus Bare-Metal Stents in Orally Anticoagulated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1633-1642.	1.1	11
502	Percutaneous Coronary Interventions in Patients Requiring Long-Term OralÂAnticoagulation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1643-1645.	1.1	0
503	The safety and efficacy of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention. <i>Medicine (United States)</i> , 2017, 96, e8015.	0.4	7
504	Is it possible to perform gastric endoscopic submucosal dissection without discontinuation of a single antiplatelet of thienopyridine derivatives?. <i>Endoscopy International Open</i> , 2017, 05, E943-E949.	0.9	6
505	Atrial fibrillation, bleeding, and coronary intervention. <i>Coronary Artery Disease</i> , 2017, 28, 702-709.	0.3	0
508	Medical Management of Pulmonary Embolism: Beyond Anticoagulation. <i>Techniques in Vascular and Interventional Radiology</i> , 2017, 20, 152-161.	0.4	4
509	Should We Still Have Bare-Metal StentsÂAvailable in Our CatheterizationÂLaboratory?. <i>Journal of the American College of Cardiology</i> , 2017, 70, 607-619.	1.2	32
510	Age is not a bar to PCI: Insights from the longâ€term outcomes from offâ€site PCI in a realâ€world setting. <i>Journal of Interventional Cardiology</i> , 2017, 30, 347-355.	0.5	14
511	Editorial Commentary: Deconstructing the dogma: Its time to untangle and reassess acute myocardial infarction care. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 492-493.	2.3	0
512	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 3341-3350.	1.0	59
513	Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 681-693.	0.6	4
514	Management of atrial fibrillation and concomitant coronary artery disease. <i>Continuing Cardiology Education</i> , 2017, 3, 47-55.	0.4	8
515	New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation. <i>Heart and Vessels</i> , 2017, 32, 1285-1295.	0.5	0
516	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. <i>Internal and Emergency Medicine</i> , 2017, 12, 923-934.	1.0	4
517	Atrial Fibrillation and Stent Selection (Bare Metal vs Drug Eluting) (from Medicare Claims). <i>American Journal of Cardiology</i> , 2017, 120, 1557-1561.	0.7	1
518	Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 248, 369-375.	0.8	22
519	Update on antithrombotic therapy after percutaneous coronary revascularisation. <i>Lancet, The</i> , 2017, 390, 810-820.	6.3	25
520	A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1491-1497.	0.8	5

#	ARTICLE	IF	CITATIONS
522	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Cardiology</i> , 2017, 40, 1264-1270.	0.7	2
523	Warfarin Prophylaxis for Anterior Infarction: Another Black Mark for Triple Therapy. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 557-558.	0.3	0
528	Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 319-324.	1.3	10
529	Platelet pathophysiology, pharmacology, and function in coronary artery disease. <i>Coronary Artery Disease</i> , 2017, 28, 614-623.	0.3	22
530	The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1209-1211.	0.8	4
531	Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior STâ€œSegment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	19
533	Anticoagulation after coronary stenting: a systemic review. <i>British Medical Bulletin</i> , 2017, 123, 79-89.	2.7	5
535	O PIONEERs!. <i>Circulation</i> , 2017, 135, 334-337.	1.6	27
536	Prasugrel in percutaneous coronary intervention (<scp>PIPCI</scp>): a single centre study. <i>Journal of Pharmacy Practice and Research</i> , 2017, 47, 193-199.	0.5	0
537	Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. <i>Cardiovascular Research</i> , 2017, 113, 61-69.	1.8	25
538	Triple Antithrombotic Therapy and Outcomes in Postâ€œPCI Patients Undergoing Nonâ€œcardiac Surgery. <i>World Journal of Surgery</i> , 2017, 41, 423-432.	0.8	3
539	Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study). <i>American Journal of Cardiology</i> , 2017, 119, 268-274.	0.7	12
540	Acute myocardial infarction. <i>Lancet, The</i> , 2017, 389, 197-210.	6.3	869
541	Is a bare-metal stent still useful for improving the outcome of percutaneous coronary intervention? From the FU-Registry. <i>Journal of Cardiology</i> , 2017, 69, 652-659.	0.8	4
542	Update on primary PCI for patients with STEMI. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 95-102.	2.3	18
543	Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 7-17.	1.0	31
544	Percutaneous Treatment of Cardiovascular Diseases in Women. , 2017, , .		0
545	Frequency and predictors of bleeding events after 2nd generation drug-eluting stent implantation differ depending on time after implantation. <i>Journal of Cardiology</i> , 2017, 69, 632-639.	0.8	3

#	ARTICLE	IF	CITATIONS
546	Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Journal of Cardiology</i> , 2017, 69, 648-651.	0.8	17
547	Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry "POL-TAVI. <i>International Journal of Cardiology</i> , 2017, 227, 305-311.	0.8	28
548	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Interventional Cardiology Clinics</i> , 2017, 6, 91-117.	0.2	4
551	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Europace, 2017, 19, 1757-1758.	0.7	107
552	Antithrombotic therapy for acute coronary syndrome: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1240-1248.	1.8	41
553	Platelets, Haemostasis and Inflammation. <i>Cardiac and Vascular Biology</i> , 2017, , .	0.2	5
554	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2215-2236.	1.8	41
556	Efficacy and Safety of Triple Therapy and Dual Therapy With Direct Oral Anticoagulants Compared to Warfarin. <i>International Heart Journal</i> , 2017, 58, 570-576.	0.5	5
557	Antithrombotic Therapy: Focus on the Elderly. <i>Cardiovascular Innovations and Applications</i> , 2017, 2, .	0.1	1
558	Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 81154-81166.	0.8	7
559	Antiplatelet Therapy Combinations and Thrombogenicity in Patients with Non-Valvular Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2017, 47, 366.	0.7	6
560	Triple antithrombotic therapy in patients undergoing percutaneous coronary intervention: balancing between ischemia and bleeding. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S128-S130.	0.7	0
561	Fibrilaci3n auricular: enfoque para el m3dico no cardiólogo. <i>latreia</i> , 2017, 30, 404-422.	0.1	3
562	Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S66-S68.	0.7	1
563	Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 423-431.	1.0	9
564	Direct oral anticoagulant and antiplatelet combination therapy: Hemorrhagic events in coronary artery stent recipients. <i>Journal of Clinical Neuroscience</i> , 2018, 50, 24-29.	0.8	3
566	Anticoagulant Strategies for Electrophysiology Procedures. , 2018, , 239-251.		0
567	Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?. <i>Clinical Research in Cardiology</i> , 2018, 107, 533-538.	1.5	21

#	ARTICLE	IF	CITATIONS
568	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. <i>Current Medical Research and Opinion</i> , 2018, 34, 1945-1957.	0.9	2
569	Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatelet Atrial Fibrillation (GRAPE-AF) Registry. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 191-196.	1.3	6
571	The times they are a changin'1. <i>European Heart Journal</i> , 2018, 39, 1736-1739.	1.0	3
572	Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENTâ€AF (The internAtional stENT â€“ Atrial Fibrillation study) multicenter registry. <i>Clinical Cardiology</i> , 2018, 41, 470-475.	0.7	15
573	Antithrombotic Therapy for Patients with Atrial Fibrillation. , 2018, , 217-238.		0
575	Antithrombotic therapy trends in non-valvular atrial fibrillation patients undergoing percutaneous coronary stent implantation: Results from a survey among fellows at the Japanese College of Cardiology. <i>Journal of Cardiology</i> , 2018, 72, 113-119.	0.8	6
577	Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI â€“ State-of-the-art review. <i>International Journal of Cardiology</i> , 2018, 264, 39-44.	0.8	2
578	Contemporary approach to stroke prevention in atrial fibrillation: Risks, benefits, and new options. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 469-480.	2.3	1
579	Venous thromboembolism controversies. <i>Disease-a-Month</i> , 2018, 64, 408-444.	0.4	3
580	Anticoagulation Management After Transcatheter and Surgical Valve Replacement. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 42.	0.4	6
581	Dual Antithrombotic Therapy with Clopidogrel and Novel Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Real-world Study. <i>Cardiology and Therapy</i> , 2018, 7, 79-87.	1.1	5
582	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	1.0	133
583	Meta-Analysis of Antithrombotic Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2018, 121, 1200-1206.	0.7	10
584	Dual (Anticoagulant Plus Single Antiplatelet) vs Triple (Anticoagulant Plus Dual Antiplatelet) Antithrombotic Therapy â€“ â€œReal Worldâ€•Experience. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 531-536.	1.6	7
585	Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 491-499.	1.6	2
586	Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 524-530.	1.6	5
587	Recent Developments in Sex-Related Differences in Presentation, Prognosis, and Management of Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2018, 34, 390-399.	0.8	28
589	More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapyâ€“Current Data and Future Directions. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11

#	ARTICLE	IF	CITATIONS
590	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2018, 378, 484-486.	13.9	13
592	The challenges of antithrombotic therapy in patients with left ventricular thrombosis. <i>European Heart Journal</i> , 2018, 39, 209-211.	1.0	2
593	A COMPASS to REACH the right patients with thrombocardiology: benefits, risks, and future of the new concept. <i>European Heart Journal</i> , 2018, 39, 758-761.	1.0	5
594	Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?. <i>Current Atherosclerosis Reports</i> , 2018, 20, 4.	2.0	8
595	Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 177-182.	0.5	4
596	Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 251-258.	1.0	3
597	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 465-473.	1.9	7
599	Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2018, 121, 718-724.	0.7	43
600	The Evolving Face of Myocardial Reperfusion in Acute Coronary Syndromes: A Primer for the Internist. <i>Mayo Clinic Proceedings</i> , 2018, 93, 199-216.	1.4	1
601	Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS. <i>Herz</i> , 2018, 43, 11-19.	0.4	2
602	Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. <i>American Heart Journal</i> , 2018, 196, 105-112.	1.2	80
603	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	0.8	181
604	Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. <i>Hospital Practice (1995)</i> , 2018, 46, 22-29.	0.5	0
607	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 514-523.	1.6	11
608	Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry. <i>International Journal of Cardiology</i> , 2018, 253, 35-39.	0.8	7
609	Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. <i>American Heart Journal</i> , 2018, 197, 77-84.	1.2	8
610	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 36-45.	1.4	14
611	Antithrombotic drugs in cardiovascular medicine. <i>Current Opinion in Cardiology</i> , 2018, 33, 369-374.	0.8	3

#	ARTICLE	IF	CITATIONS
612	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. <i>American Heart Journal</i> , 2018, 200, 44-50.	1.2	111
613	Coronary Artery Disease in Patients ≥80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2015-2040.	1.2	175
614	Arrhythmias in Patients ≥80 Years of Age. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2041-2057.	1.2	94
615	Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation: update. <i>Heart</i> , 2018, 104, 1976-1983.	1.2	7
616	Pharmacotherapy in Acutely Anemic Jehovah's Witnesses: An Evidence-Based Review. <i>Annals of Pharmacotherapy</i> , 2018, 52, 910-919.	0.9	7
617	An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018, 200, 17-23.	1.2	69
618	Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018, 118, S34-S44.	1.8	1
619	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Where Are We Now?. <i>Annals of Pharmacotherapy</i> , 2018, 52, 884-897.	0.9	1
620	Percutaneous coronary intervention: 2017 in review. <i>Journal of Interventional Cardiology</i> , 2018, 31, 117-128.	0.5	8
621	Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study. <i>Heart and Vessels</i> , 2018, 33, 986-996.	0.5	1
622	Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2018, 13, 1019-1028.	1.0	2
623	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e40-e45.	0.6	2
624	Is it Time to Abandon Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation on Anticoagulation?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 635-637.	1.1	2
625	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
626	Antiplatelet and Anticoagulant Drugs. , 2018, , 303-320.		1
627	Prevention of Bleeding in Patients With Atrial Fibrillation Undergoing PCI (PIONEER): Three May End Up Being a Crowd. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 393-395.	0.7	4
628	Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review. <i>Journal of Pharmacy Practice</i> , 2018, 31, 335-341.	0.5	1
629	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	1.0	2,246

#	ARTICLE	IF	CITATIONS
630	Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. <i>European Heart Journal</i> , 2018, 39, 201-208.	1.0	88
631	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	0.6	261
632	Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 301-307.	0.7	19
633	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018, 11, 5-12.	1.0	17
634	Acute Management of Atrial Fibrillation. <i>Cardiology Clinics</i> , 2018, 36, 141-159.	0.9	11
636	Dosing issues with non-vitaminÅK antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 85-94.	0.7	29
637	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
638	Thromboembolic and bleeding risk management in elderly patients: a case report. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 1011-1013.	1.4	0
639	Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS. <i>Herz</i> , 2018, 43, 20-25.	0.4	5
640	Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2018, 14, 89-99.	0.5	0
641	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018, 197, 133-141.	1.2	17
643	Bleeding in advanced CKD patients on antithrombotic medication â€“ A critical appraisal. <i>Pharmacological Research</i> , 2018, 129, 535-543.	3.1	16
644	Perioperative management of anticoagulant and antiplatelet therapy. <i>Heart</i> , 2018, 104, 1461-1467.	1.2	59
645	Anticoagulation in atrial fibrillation. <i>Herz</i> , 2018, 43, 2-10.	0.4	6
646	Patients with atrial fibrillation and coronary artery disease â€“ Double trouble. <i>Advances in Medical Sciences</i> , 2018, 63, 30-35.	0.9	142
647	Heart-breaking aspirin interruption. <i>Journal of Thoracic Disease</i> , 2018, 10, 30-34.	0.6	1
648	A Review of Triple Therapy in Acute Coronary Syndromes. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 166-173.	0.6	0
649	<i>Does the Presence of Subdural Hemorrhage Increase the Risk of Intracranial Hemorrhage Expansion after the Initiation of Antithrombotic Medication?</i>. <i>American Surgeon</i> , 2018, 84, 416-421.	0.4	6

#	ARTICLE	IF	CITATIONS
650	Combining anticoagulation and antiplatelet drugs in coronary artery disease. Australian Prescriber, 2018, 41, 111-115.	0.5	6
651	6 PBM im nicht chirurgischen Bereich. , 2018, , .		0
653	Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation. Coronary Artery Disease, 2018, 29, 670-680.	0.3	3
654	2018 Korean Guideline of Atrial Fibrillation Management. Korean Circulation Journal, 2018, 48, 1033.	0.7	108
655	The Role of Double and Triple Therapy with Direct Oral Anticoagulants in Coronary Artery Disease, Peripheral Artery Disease, and Stroke. Clinical Therapeutics, 2018, 40, 1907-1917.e3.	1.1	3
656	Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS ONE, 2018, 13, e0205457.	1.1	5
657	lbrutinib-related bleeding. Blood Coagulation and Fibrinolysis, 2018, 29, 481-487.	0.5	17
658	Recomendaciones del manejo antiagregante en Cardiología. Documento de revisión de la Sociedad Andaluza de Cardiología. Cardiocore, 2018, 53, e13-e31.	0.0	0
659	Triple therapy after PCI – Warfarin treatment quality and bleeding risk. PLoS ONE, 2018, 13, e0209187.	1.1	3
660	Sex Differences in Long-Term Clinical Outcomes in Patients With Atrial Fibrillation Undergoing Coronary Stent Implantation. Circulation Journal, 2018, 82, 1754-1762.	0.7	2
661	Uso de anticoagulantes orales en situaciones clínicas complejas con fibrilación auricular. Medicina Clínica, 2018, 150, 8-24.	0.3	2
662	Antiplatelet agents in uncertain clinical scenarios – a bleeding nightmare. Cardiovascular Diagnosis and Therapy, 2018, 8, 647-662.	0.7	7
663	Antithrombotic Regimens in Patients With Percutaneous Coronary Intervention Whom an Anticoagulant Is Indicated: A Systematic Review and Network Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 1322.	1.6	5
664	Antithrombotic Treatment in Patients Undergoing Transcatheter Aortic Valve Replacement. , 2018, , 605-613.		0
665	Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome. Journal of the American College of Cardiology, 2018, 72, 2886-2903.	1.2	68
666	ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2018, 72, 2915-2931.	1.2	273
667	A quality framework for the role of invasive, non-interventional cardiologists in the present-day cardiac catheterization laboratory: A multidisciplinary SCAI/HFSA expert consensus statement. Catheterization and Cardiovascular Interventions, 2018, 92, 1356-1364.	0.7	2
669	Management of Anticoagulation in Patients with Atrial Fibrillation Undergoing PCI: Double or Triple Therapy?. Current Cardiology Reports, 2018, 20, 110.	1.3	4

#	ARTICLE	IF	CITATIONS
670	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1041-1052.	1.0	20
671	Conundrum of Using Real-World Observational Data to Inform Real-World Conclusions About Safety and Efficacy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1801-1803.	1.2	0
672	Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1790-1800.	1.2	41
673	DAPT plus anticoagulant therapy: The difficult coexistence post-ACS in older patients with atrial fibrillation. <i>Monaldi Archives for Chest Disease</i> , 2018, 88, 957.	0.3	2
674	Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 1675-1690.	1.3	5
675	Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2018, 11, e005356.	1.6	7
676	Elderly Patient Management Problems: Antithrombotic Therapy Selection Features. <i>Clinical Case. Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 515-523.	0.3	0
677	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation – The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 2983-2991.	0.7	16
680	Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 715-723.	0.6	1
682	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. <i>BMC Medicine</i> , 2018, 16, 158.	2.3	15
683	Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?. <i>Cardiovascular Innovations and Applications</i> , 2018, 3, .	0.1	0
684	Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. <i>IJC Heart and Vasculature</i> , 2018, 20, 56-62.	0.6	34
685	Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation – Rationale and design of the ENVISAGE-TAVI AF trial. <i>American Heart Journal</i> , 2018, 205, 63-69.	1.2	62
686	Antiplatelet Treatment for Catheter-Based Interventions in High-Risk Patients: Current Guidelines and Expert Opinion. <i>Hamostaseologie</i> , 2018, 38, 229-235.	0.9	2
687	Anticoagulation in Atherosclerotic Disease. <i>Hamostaseologie</i> , 2018, 38, 240-246.	0.9	14
688	Novel aspects of antiplatelet therapy in cardiovascular disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 439-449.	1.0	41
690	Meta-Analysis Comparing Dual Versus Single Antiplatelet Therapy in Combination With Antithrombotic Therapy in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention With Stent Implantation. <i>American Journal of Cardiology</i> , 2018, 122, 604-611.	0.7	13
691	Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: the OLTAT registry. <i>International Journal of Cardiology</i> , 2018, 264, 64-69.	0.8	19

#	ARTICLE	IF	CITATIONS
692	Treatment of Intracranial Atherosclerotic Stenoses. , 2018, , 1099-1123.		0
693	Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 502-508.	1.0	9
694	Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 287-294.	1.3	31
695	Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis. <i>Open Heart</i> , 2018, 5, e000785.	0.9	15
697	Managing Antithrombotic Agents in the Setting of Acute Gastrointestinal Bleeding. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2018, 28, 351-361.	0.6	6
698	Triple Therapy: When, if Ever?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 61.	0.4	1
699	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
700	Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	2
701	Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose. <i>Current Treatment Options in Neurology</i> , 2018, 20, 32.	0.7	4
703	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
704	Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 120.	0.7	7
705	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. <i>Heart Lung and Circulation</i> , 2018, 27, 1209-1266.	0.2	216
706	The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly. <i>Frontiers in Physiology</i> , 2018, 9, 876.	1.3	9
707	Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice. <i>American Heart Journal</i> , 2018, 203, 74-81.	1.2	2
708	Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI. <i>Scientific Reports</i> , 2018, 8, 10326.	1.6	2
709	Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. <i>Journal of Clinical Medicine</i> , 2018, 7, 74.	1.0	5
710	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 766-790.	0.8	44
711	Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1239-1246.	0.7	5

#	ARTICLE	IF	CITATIONS
712	LMU Munich: platelet inhibition novel aspects on platelet inhibition and function. <i>Clinical Research in Cardiology</i> , 2018, 107, 30-39.	1.5	23
713	Patients with atrial fibrillation and coronary events: are we any closer to coming out from the labyrinth of the various antithrombotic strategies?. <i>Heart</i> , 2018, 104, 878-879.	1.2	2
714	Atrial fibrillation, intra-ventricular thrombus, and other anticoagulant indications relationship with adverse outcomes in acute anterior myocardial infarction patients. <i>Journal of Cardiology</i> , 2018, 72, 277-283.	0.8	2
715	Left Ventricular Thrombus After Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2018, 3, 642.	3.0	171
716	Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!. <i>Netherlands Heart Journal</i> , 2018, 26, 334-340.	0.3	5
718	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 205, 110-117.	1.2	22
719	In Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, One Size Cannot Fit All. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1538-1539.	1.1	0
720	Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. <i>PLoS ONE</i> , 2018, 13, e0202575.	1.1	38
721	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. <i>American Heart Journal</i> , 2018, 205, 77-86.	1.2	6
722	Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018, 273, 80-87.	0.8	7
723	Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1426-1436.	0.8	10
724	Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble. <i>Drugs</i> , 2018, 78, 1309-1319.	4.9	1
725	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1121-1201.	0.4	718
726	Effects of clopidogrel with or without aspirin on the generation of extracellular vesicles in the microcirculation and in venous blood: A randomized placebo controlled trial. <i>Thrombosis Research</i> , 2018, 167, 149-155.	0.8	4
727	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.0	25
728	Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 501-514.	0.6	2
729	Predictors and consequences of postdischarge gastrointestinal bleeding after percutaneous coronary intervention. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12440.	1.1	3
730	Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2018, 82, 2016-2024.	0.7	8

#	ARTICLE	IF	CITATIONS
731	Utilization of Anticoagulant and Antiplatelet Agents Among Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention—Retrospective Cohort Study Using a Nationwide Claims Database in Japan. <i>Circulation Journal</i> , 2018, 82, 361-368.	0.7	9
732	Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0199232.	1.1	4
733	Antithromboembolic Strategies for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 441-455.	1.0	0
734	Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy. , 2019, 193, 83-90.		16
735	The Role of Direct Oral Anticoagulants in Patients With Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 103-112.	1.0	9
736	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
737	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
738	2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm So. <i>Europace</i> , 2019, 21, 192-193.	0.7	209
739	Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007604.	1.4	10
740	Atrial fibrillation and coronary stenting: is the AUGUSTUS trial the end of triple therapy?. <i>Future Cardiology</i> , 2019, 15, 319-321.	0.5	0
741	Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e012741.	1.6	27
742	Triple or dual antithrombotic therapy postpercutaneous coronary intervention: Which one is better?. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2473-2474.	0.8	0
743	Efficacy and safety of single vs dual antiplatelet therapy in patients on anticoagulation undergoing percutaneous coronary intervention: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2460-2472.	0.8	7
744	Translational Research and Early Favorable Clinical Results of a Novel Polyphosphazene (Polyzene-F) Nanocoating. <i>Regenerative Engineering and Translational Medicine</i> , 2019, 5, 341-353.	1.6	21
745	Anti-thrombotic therapy strategies with long-term anticoagulation after percutaneous coronary intervention— a systematic review and meta-analysis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2019, 9, 203-210.	0.4	4
746	Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials. <i>Clinical Cardiology</i> , 2019, 42, 839-846.	0.7	7
747	Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 425-433.	1.3	0
748	Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?. <i>IJC Heart and Vasculature</i> , 2019, 24, 100404.	0.6	0

#	ARTICLE	IF	CITATIONS
749	Management of Antithrombotic Therapy in Atrial Fibrillation Patients UndergoingÂPCI. Journal of the American College of Cardiology, 2019, 74, 83-99.	1.2	126
750	Antithrombotics. Journal of the American College of Cardiology, 2019, 74, 699-711.	1.2	24
751	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal, 2019, 40, 3757-3767.	1.0	211
752	Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry. Journal of Arrhythmia, 2019, 35, 593-601.	0.5	3
753	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. American Journal of Medicine, 2019, 132, 1431-1440.e7.	0.6	8
754	Antithrombotic therapy in acute coronary syndrome and stable coronary artery disease patients with atrial fibrillation: a 3-year retrospective cohort study. Personalized Medicine, 2019, 16, 399-407.	0.8	0
755	eCLASS: Edge-Cloud-Log Assuring-Secrecy Scheme for Digital Forensics. Symmetry, 2019, 11, 1192.	1.1	5
756	Ischemic and bleeding outcomes of triple therapy in patients on chronic anticoagulation undergoing percutaneous coronary intervention: A meta-analysis of randomized trials. JRSM Cardiovascular Disease, 2019, 8, 204800401988557.	0.4	3
757	Fifty years of research on antithrombotic therapy: Achievements and disappointments. European Journal of Internal Medicine, 2019, 70, 1-7.	1.0	17
758	Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2
759	Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovascular Drugs and Therapy, 2019, 33, 511-521.	1.3	5
760	<p>Using non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1183-1206.	0.9	6
761	A Straightforward Oneâ€Step Access to Ticlopidine Derivatives Arylated at the C5â€Position of the Thienyl Ring via Pdâ€Catalyzed Direct Arylations. Asian Journal of Organic Chemistry, 2019, 8, 2155-2161.	1.3	3
762	Atrial Fibrillation and Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e008269.	1.4	0
763	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in AtrialÂFibrillation Patients After PCI. JACC: Cardiovascular Interventions, 2019, 12, 1553-1561.	1.1	9
764	The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial. Trials, 2019, 20, 520.	0.7	5
765	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting. American Journal of Health-System Pharmacy, 2019, 76, 1395-1402.	0.5	2
766	Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. New England Journal of Medicine, 2019, 381, 1103-1113.	13.9	342

#	ARTICLE	IF	CITATIONS
767	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus. <i>JACC Basic To Translational Science</i> , 2019, 4, 763-775.	1.9	12
768	Authors' Reply to "Underlying Differences in the Treatment of Left Ventricular Thrombus With Non-Vitamin K Antagonist Oral Anticoagulants". <i>American Journal of Cardiology</i> , 2019, 124, 1489-1491.	0.7	0
769	Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. <i>Atherosclerosis</i> , 2019, 289, 118-125.	0.4	6
770	When to withhold oral anticoagulation in atrial fibrillation – an overview of frequent clinical discussion topics. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 399-408.	1.0	16
771	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 1921-1932.	1.6	57
772	Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 135-142.	0.2	22
773	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. <i>Circulation</i> , 2019, 140, e125-e151.	1.6	1,925
775	2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. <i>Heart Rhythm</i> , 2019, 16, e66-e93.	0.3	282
776	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 104-132.	1.2	1,458
778	Antithrombotic Agents. <i>Circulation Research</i> , 2019, 124, 426-436.	2.0	76
779	Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 343-348.	1.0	7
780	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". <i>Circulation Research</i> , 2019, 124, e119.	2.0	2
781	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	3.0	198
782	Impact of Total Antithrombotic Effect on Bleeding Complications in Patients Receiving Multiple Antithrombotic Agents. <i>Circulation Journal</i> , 2019, 83, 1309-1316.	0.7	4
783	The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 516-518.	1.0	1
784	Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of the Medical Sciences</i> , 2019, 358, 95-103.	0.4	4
785	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. <i>American Heart Journal</i> , 2019, 213, 81-90.	1.2	10
786	Warfarin therapy in Chinese patients with atrial fibrillation treated with percutaneous coronary intervention: a 5 year follow-up retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2019, 35, 1777-1783.	0.9	3

#	ARTICLE	IF	CITATIONS
787	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 226-236.	1.4	31
788	Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2019, 60, 546-553.	0.5	2
789	Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?. <i>IJC Heart and Vasculature</i> , 2019, 23, 100369.	0.6	7
790	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
791	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
792	Previous Antithrombotic Therapy, Particularly Anticoagulant, Is Associated with Unfavorable Outcomes in Patients with Primary Spontaneous Intracerebral Hemorrhage Receiving Craniotomy: A Nationwide Population-Based Cohort Study. <i>World Neurosurgery</i> , 2019, 128, e59-e73.	0.7	4
794	Dual versus triple therapy for patients with atrial fibrillation and acute coronary syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 511-513.	1.0	5
796	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1509-1524.	13.9	833
797	Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. <i>JAMA Internal Medicine</i> , 2019, 179, 533.	2.6	37
798	Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post-acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS-TIMI 46 and ATLAS ACS-TIMI 51. <i>Journal of the American Heart Association</i> , 2019, 8, .	1.6	10
799	Thromboembolic and Bleeding Complications in Transcatheter Aortic Valve Implantation: Insights on Mechanisms, Prophylaxis and Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 280.	1.0	31
800	STEMIs and Coumadin: Are they an unsafe combination?. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E257-E258.	0.7	0
801	Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and meta-regression. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1134-1139.	0.3	3
802	Antiplatelet Drugs in the Management of Coronary Artery Disease. , 2019, , 1017-1029.		0
803	Atrial fibrillation, with ACS and PCI: walking a tightrope. <i>European Heart Journal</i> , 2019, 40, 1563-1566.	1.0	5
804	Development of New Antithrombotic Regimens for Patients with Acute Coronary Syndrome. <i>Clinical Drug Investigation</i> , 2019, 39, 495-502.	1.1	3
805	Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. <i>Thrombosis Research</i> , 2019, 177, 180-186.	0.8	4
806	Rate and impact of venous thromboembolism in patients with ST-segment elevation myocardial infarction: Analysis of the Nationwide Inpatient Sample database 2003-2013. <i>Vascular Medicine</i> , 2019, 24, 341-348.	0.8	4

#	ARTICLE	IF	CITATIONS
807	Worse 12-month prognosis in women with non-valvular atrial fibrillation undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2019, 178, 20-25.	0.8	3
809	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	1.0	62
810	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019, 35, 619-633.	0.8	48
811	Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner?. <i>Thrombosis Research</i> , 2019, 176, 133-139.	0.8	3
812	Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry). <i>American Journal of Cardiology</i> , 2019, 123, 1293-1300.	0.7	16
813	Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 3.	0.4	0
814	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. <i>American Heart Journal</i> , 2019, 212, 13-22.	1.2	13
815	Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2019, , 481-497.	0.0	0
816	One-Year Outcomes of Patients With Established Coronary Artery Disease Presenting With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 1387-1392.	0.7	8
817	Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 35, 3-44.	0.2	4
818	For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?. <i>Canadian Journal of Hospital Pharmacy</i> , 2019, 72, .	0.1	0
819	Complex management of atrial fibrillation. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 702-706.	0.5	0
820	Evolving Field of Long-term Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation. <i>American Journal of the Medical Sciences</i> , 2019, 358, 91-92.	0.4	0
821	Real-World Antithrombotic Therapy in Atrial Fibrillation Patients with a History of Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2019, 60, 1321-1327.	0.5	5
822	Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008160.	1.4	1
823	Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013252.	1.5	8
824	Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data. <i>PLoS ONE</i> , 2019, 14, e0225297.	1.1	13
825	Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2019, 30, 177-182.	0.3	0

#	ARTICLE	IF	CITATIONS
826	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2346-2355.	1.1	13
827	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	1.1	8
828	Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. <i>Journal of Clinical Medicine</i> , 2019, 8, 2016.	1.0	5
830	Omitting aspirin in PCI patients: Myth or reality?. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 711-724.	1.3	4
831	Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 75, 1.	0.8	10
832	Impact of Postdischarge Bleeding on Long-Term Mortality in Percutaneous Coronary Intervention Patients Taking Oral Anticoagulants. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 210-217.	0.8	0
833	Benefits and Risks of Anticoagulation in Acute Coronary Syndrome. <i>American Journal of Therapeutics</i> , 2019, 26, e198-e207.	0.5	1
834	The Basics of Antithrombotic Medications. <i>Topics in Geriatric Rehabilitation</i> , 2019, 35, 55-71.	0.2	0
835	Continual measurement of arterial dP/dtmax enables minimally invasive monitoring of left ventricular contractility in patients with acute heart failure. <i>Critical Care</i> , 2019, 23, 364.	2.5	18
836	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure—Digest Version. <i>Circulation Journal</i> , 2019, 83, 2084-2184.	0.7	446
837	Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 74, 82-90.	0.8	5
838	Atrial Fibrillation, Diabetes, and Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2356-2358.	1.1	0
839	Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. <i>European Heart Journal</i> , 2019, 40, 3768-3770.	1.0	11
840	Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471989168.	1.0	6
841	Antithrombotic Management After Intracranial Hemorrhage. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 88.	0.4	2
842	Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2019, 30, 109-115.	0.3	1
843	Antithrombotic Management of Ischemic Stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 78.	0.4	9
844	Short-term versus long-term triple antithrombotic therapy for patients with coronary stents and requiring oral anticoagulation. <i>Coronary Artery Disease</i> , 2019, 30, 116-123.	0.3	0

#	ARTICLE	IF	CITATIONS
845	Pharmacodynamic safety of clopidogrel monotherapy in patients under oral anticoagulation with a vitamin K antagonist undergoing coronary stent implantation. <i>Platelets</i> , 2019, 30, 714-719.	1.1	2
846	The Hypercholesterolemia Paradox in Percutaneous Coronary Intervention: An Analysis of a Multicenter PCI Registry. <i>Internal Medicine</i> , 2019, 58, 345-353.	0.3	6
847	Anticoagulation strategy in patients with atrial fibrillation after carotid endarterectomy. <i>Acta Chirurgica Belgica</i> , 2019, 119, 209-216.	0.2	7
848	Anticoagulation in the cardiac patient: A concise review. <i>European Journal of Haematology</i> , 2019, 102, 3-19.	1.1	9
849	Bleeding risk score in Japanese patients on antiplatelets plus an anticoagulant. <i>Journal of Cardiology</i> , 2019, 73, 466-467.	0.8	2
850	Antithrombotic Medication and the Risk of Vitreous Hemorrhage in Atrial Fibrillation: Korean National Health Insurance Service National Cohort. <i>Yonsei Medical Journal</i> , 2019, 60, 65.	0.9	7
851	Reply to: Dual vs. triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2019, 40, 218-219.	1.0	1
852	Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). <i>American Journal of Cardiology</i> , 2019, 123, 355-360.	0.7	6
853	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2018. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2019, 33, 2-11.	0.6	5
854	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
855	Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 359-364.	1.0	2
856	Advances in Antiplatelet and Anticoagulant Therapies for NSTEMI-ACS. <i>Current Cardiology Reports</i> , 2019, 21, 3.	1.3	9
857	Antithrombotic therapy after acute coronary syndromes in patients with atrial fibrillation: Shouldn't we pay more attention to the risk of ischemic and thromboembolic events?. <i>International Journal of Cardiology</i> , 2019, 276, 38-39.	0.8	1
858	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007411.	1.4	55
859	Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban. <i>Pharmacology</i> , 2019, 103, 17-22.	0.9	4
860	Relationship of left ventricular thrombus formation and adverse outcomes in acute anterior myocardial infarction in patients treated with primary percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2019, 42, 69-75.	0.7	16
861	Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: An all-comers registry study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 893-900.	0.7	29
862	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. <i>International Journal of Cardiology</i> , 2019, 275, 39-45.	0.8	12

#	ARTICLE	IF	CITATIONS
863	Patients Taking Oral Anticoagulants for Atrial Fibrillation With Concomitant Complex Disease States. , 2019, , 149-159.		0
864	Radiofrequency catheter ablation prior to percutaneous coronary intervention in patients with atrial fibrillation coexisting with stable coronary artery disease: a single-center pilot study. Heart and Vessels, 2019, 34, 632-640.	0.5	7
866	Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation, 2019, 139, 604-616.	1.6	117
867	Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention. Journal of Cardiology, 2019, 73, 1-6.	0.8	12
868	In-hospital outcomes of STEMI patients on warfarin undergoing primary PCI. Catheterization and Cardiovascular Interventions, 2019, 93, 41-47.	0.7	3
869	Oral Anticoagulants With Dual Antiplatelet Therapy Versus Clopidogrel in Patients After Percutaneous Coronary Intervention: A Meta-Analysis. American Journal of Therapeutics, 2019, 26, e143-e150.	0.5	3
870	Modern Management of ST-Segment Elevation Myocardial Infarction. Current Problems in Cardiology, 2020, 45, 100393.	1.1	26
871	A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy. Cardiovascular Intervention and Therapeutics, 2020, 35, 150-161.	1.2	7
872	Antithrombotic therapy in atrial fibrillation: stop triple therapy and start optimizing dual therapy?. Clinical Research in Cardiology, 2020, 109, 128-130.	1.5	2
873	Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends in Cardiovascular Medicine, 2020, 30, 198-202.	2.3	4
874	Anesthesiologists Guide to the 2019 AHA/ACC/HRS Focused Update for the Management of Patients With Atrial Fibrillation. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1925-1932.	0.6	6
875	MAPT (Mono Antiplatelet Therapy) as Regular Regimen After COBRA PzFâ„¢ NanoCoated Coronary Stent (NCS) Implantation. Cardiovascular Revascularization Medicine, 2020, 21, 785-789.	0.3	11
876	Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Internal Medicine, 2020, 59, 311-321.	0.3	25
877	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace, 2020, 22, 33-46.	0.7	54
878	Anti-thrombotic strategies in elderly patients receiving platelet inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 57-68.	1.4	13
879	The myth of "stable" coronary artery disease. Nature Reviews Cardiology, 2020, 17, 9-21.	6.1	89
880	Triple, dual, and single antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention. Cardiovascular Intervention and Therapeutics, 2020, 35, 44-51.	1.2	8
881	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 128-129.	1.4	19

#	ARTICLE	IF	CITATIONS
882	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	1.0	4,210
883	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 083-093.	1.8	21
884	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E102-E109.	0.7	10
885	Meta-Analysis Comparing Double Versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 125, 19-28.	0.7	7
886	Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management. <i>Clinical Cardiology</i> , 2020, 43, 14-23.	0.7	15
887	Temporal trends in prevalence and outcomes of atrial fibrillation in patients undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2020, 43, 33-42.	0.7	8
888	Cisplatin related cardiotoxicity – acute and chronic cardiovascular morbidity in a testicular cancer survivor. <i>Scottish Medical Journal</i> , 2020, 65, 24-27.	0.7	3
889	Towards appropriate polypharmacy in older cardiovascular patients: How many medications do I have to take?. <i>Clinical Cardiology</i> , 2020, 43, 137-144.	0.7	16
890	Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2020, 302, 95-102.	0.8	30
891	Current status of percutaneous coronary intervention in patients with atrial fibrillation: The Fushimi AF Registry. <i>Journal of Cardiology</i> , 2020, 75, 513-520.	0.8	3
892	Effect of Renal Dysfunction on the Risks for Ischemic and Bleeding Events in Patients With Atrial Fibrillation Receiving Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 125, 399-408.	0.7	3
893	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	0.8	12
894	Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 19-29.	1.2	37
895	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or) <small>Tj, ETQq1 1 0.7843</small>	0.7	13
896	Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 41-44.	0.8	4
897	Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy – Reply. <i>JAMA Cardiology</i> , 2020, 5, 111.	3.0	1
898	From the Choice of a Regimen to the Choice of an Intensity: Changing Perspective in the Antithrombotic Therapy of Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 143-144.	1.3	1
899	Long-term antithrombotic therapy after venous stent placement. <i>Phlebology</i> , 2020, 35, 402-408.	0.6	11

#	ARTICLE	IF	CITATIONS
900	Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 125, 521-527.	0.7	18
901	Dual-Antithrombotic Therapy With DOACs After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. <i>Canadian Journal of Cardiology</i> , 2020, 36, 135-142.	0.8	9
902	Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. <i>Coronary Artery Disease</i> , 2020, 31, 260-265.	0.3	1
903	Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome. <i>Coronary Artery Disease</i> , 2020, 31, 66-72.	0.3	8
904	Safety and efficacy of dual versus triple antithrombotic therapy (DAT vs TAT) in patients with atrial fibrillation following a PCI: a systematic review and network meta-analysis. <i>BMJ Open</i> , 2020, 10, e036138.	0.8	5
905	Ticagrelor Versus Clopidogrel in Older Patients with NSTEMI-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3249.	1.0	5
906	Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry). <i>American Journal of Cardiology</i> , 2020, 133, 182-184.	0.7	0
907	Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Cardiology Clinics</i> , 2020, 38, 551-561.	0.9	2
908	Double Antithrombotic versus Triple Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. <i>International Journal of Angiology</i> , 2020, 29, 081-087.	0.2	0
909	Novel Oral Anticoagulants Following Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008465.	1.4	6
910	In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo. <i>Annals of Internal Medicine</i> , 2020, 173, JC29.	2.0	0
911	Does aspirin prevent venous thromboembolism?. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 634-641.	0.9	13
912	Combining antiplatelet and anticoagulant therapy in cardiovascular disease. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 642-648.	0.9	21
913	Novel Dual Therapy: A Paradigm Shift in Anticoagulation in Patients of Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>TH Open</i> , 2020, 04, e332-e343.	0.7	2
915	Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 587-600.	0.6	5
917	Outcome of flow diverter placement for intracranial aneurysm with dual antiplatelet therapy and oral anticoagulant therapy. <i>Interventional Neuroradiology</i> , 2020, 26, 532-538.	0.7	6
918	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020, 9, e017212.	1.6	52
919	Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View. <i>Visceral Medicine</i> , 2020, 36, 264-273.	0.5	3

#	ARTICLE	IF	CITATIONS
920	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1847-1948.	0.8	313
921	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2115-2124.	0.9	5
922	Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. <i>Journal of Clinical Medicine</i> , 2020, 9, 3474.	1.0	15
923	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. <i>Circulation</i> , 2020, 142, 1579-1590.	1.6	28
924	Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. <i>CJC Open</i> , 2020, 2, 641-651.	0.7	8
925	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant—Or, Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2673.	1.0	5
926	Stroke prevention in patients with atrial fibrillation and comorbidities: evidence and common sense. <i>Netherlands Heart Journal</i> , 2020, 28, 501-503.	0.3	0
927	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	1.2	35
928	Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. <i>The Cochrane Library</i> , 2020, 2020, CD009716.	1.5	13
929	Drugs, Devices, and Procedural Therapies to Prevent Recurrent Cardiogenic Embolic Stroke. , 2020, , 337-383.		0
930	543 Review of Frequency and Outcomes of Culturally and Linguistically Diverse Patients Presenting With Myocardial Infarction. <i>Heart Lung and Circulation</i> , 2020, 29, S281-S282.	0.2	0
931	544 Role of Medical Tutor Specialist With Cardiology Background in the Assessment and Diagnostic Unit; The North Shore Hospital Experience. <i>Heart Lung and Circulation</i> , 2020, 29, S282.	0.2	0
932	545 Safety and Efficacy of Dual Versus Triple Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Clinically Approved Doses of Chronic Anticoagulation: A Systematic Review and Meta-analysis of Randomised Controlled Trials. <i>Heart Lung and Circulation</i> , 2020, 29, S282-S283.	0.2	0
933	Updates on the use of direct oral anticoagulants for the management of chronic conditions. <i>Pharmacy Today</i> , 2020, 26, 44-58.	0.0	0
934	Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). <i>Annals of Translational Medicine</i> , 2020, 8, 392-392.	0.7	12
935	Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 269-275.	0.8	3
936	VE-1902—A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. <i>Thrombosis Research</i> , 2020, 190, 112-121.	0.8	8
938	Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. <i>Hospital Practice (1995)</i> , 2020, 48, 169-179.	0.5	42

#	ARTICLE	IF	CITATIONS
939	Fibrilaci3n auricular y cardiopat3a isqu3mica: m3s all3 de la prevenci3n del ictus. Revista Espanola De Cardiologia Suplementos, 2020, 20, 11-20.	0.2	0
940	The Combination of Oral Anticoagulant and Antiplatelet Therapies: Stay One Step Ahead. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 391-398.	1.0	6
941	Ticagrelor: A Safe Option as Part of Triple Therapy?. Clinics and Practice, 2020, 10, 1221.	0.6	2
942	Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board. Netherlands Heart Journal, 2020, 28, 504-513.	0.3	1
943	Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen. Journal of Cardiology, 2020, 76, 35-43.	0.8	5
944	Safety of direct oral anticoagulant - and antiplatelet therapy in patients with atrial fibrillation treated by carotid artery stenting. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104899.	0.7	8
945	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	1.4	1
946	Improving outcomes of percutaneous coronary interventions in patients with stable ischemic heart disease. Journal of Thoracic Disease, 2020, 12, 1740-1749.	0.6	2
947	Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. IJC Heart and Vasculature, 2020, 28, 100524.	0.6	13
948	Antithrombotic Therapy for Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention. Journal of Osteopathic Medicine, 2020, 120, 345-349.	0.4	0
949	Long-term monotherapy with ticagrelor after coronary stenting: the GLOBAL LEADERS study. European Heart Journal Supplements, 2020, 22, E46-E49.	0.0	0
950	Aspirin Discontinuation in Patients Requiring Oral Anticoagulation Undergoing Percutaneous Coronary Intervention, The Role of Procedural Complexity. Cardiovascular Drugs and Therapy, 2020, 34, 659-662.	1.3	5
951	Challenges and Controversies in the Management of ACS in Elderly Patients. Current Cardiology Reports, 2020, 22, 51.	1.3	10
952	Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 399-408.	1.0	3
953	The year in review: advances in interventional cardiology in 2019. Current Opinion in Cardiology, 2020, 35, 325-331.	0.8	1
954	Evaluation of the safety and efficacy of the Cobra <sc>PzF NanoCoated</sc> coronary stent in routine, consecutive, prospective, and high-risk patients: The <sc>eCobra</sc> study. Catheterization and Cardiovascular Interventions, 2021, 98, 45-54.	0.7	12
955	Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. Heart Lung and Circulation, 2020, 29, 1749-1757.	0.2	5
956	The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y ₁₂ Inhibitor in Patients After Percutaneous Coronary Intervention. Circulation, 2020, 142, 538-545.	1.6	98

#	ARTICLE	IF	CITATIONS
957	Optimal antiplatelet and anticoagulation strategies in acute coronary syndromes. <i>Herz</i> , 2020, 45, 528-536.	0.4	2
958	Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians. <i>International Journal of Angiology</i> , 2020, 29, 088-097.	0.2	3
959	Impact of previous coronary artery bypass grafting in patients presenting with an acute coronary syndrome: Current trends and clinical implications. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 731-740.	0.4	2
960	JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. <i>Circulation Journal</i> , 2020, 84, 831-865.	0.7	197
961	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 680.	1.0	9
962	Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists. <i>Clinical Drug Investigation</i> , 2020, 40, 343-353.	1.1	57
963	Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 357-365.	1.0	3
964	How Un-POPular Is Bleeding in Patients with TAVI?. <i>New England Journal of Medicine</i> , 2020, 382, 1761-1763.	13.9	0
965	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 1618-1627.	1.6	84
966	Looking into the next decade of antithrombotic therapy for patients with atrial fibrillation and percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 522-526.	1.0	0
967	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2020.	1.0	5
968	Antithrombotic therapy in coronary artery disease patients with atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 323.	0.7	5
969	New Antithrombotic Drugs in Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 2059.	1.0	10
970	Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Postepy W Kardiologii Interwencyjnej</i> , 2020, 16, 127-137.	0.1	1
971	Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 195, 128-135.	0.8	3
972	Dual anti-thrombotic treatment with direct anticoagulants improves clinical outcomes in patients with Atrial Fibrillation with ACS or undergoing PCI. A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0235511.	1.1	8
973	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. <i>Internal and Emergency Medicine</i> , 2020, 15, 1093-1104.	1.0	5
974	P2Y ₁₂ inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2020, 106, 575-583.	1.2	13

#	ARTICLE	IF	CITATIONS
975	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	3.0	71
976	Editorial to the "safety and efficacy of direct oral anticoagulants compared to vitamin K antagonist post percutaneous coronary artery interventions in patients with atrial fibrillation: A systematic review and meta-analysis". <i>Journal of Arrhythmia</i> , 2020, 36, 280-281.	0.5	0
978	Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. <i>Drugs and Aging</i> , 2020, 37, 359-372.	1.3	36
979	Antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty: rational convincement and supporting evidence. <i>European Journal of Internal Medicine</i> , 2020, 77, 44-51.	1.0	3
980	Incidence of dual antiplatelet therapy interruption within 1 year after primary percutaneous coronary intervention in patients with acute ST elevation myocardial infarction. <i>Postgraduate Medical Journal</i> , 2020, 96, 9-13.	0.9	0
981	Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. <i>Europace</i> , 2020, 22, 538-546.	0.7	36
982	Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. <i>Cardiovascular Intervention and Therapeutics</i> , 2020, 35, 117-129.	1.2	30
983	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
984	Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104584.	0.7	8
985	Drug-eluting versus bare-metal stents for first myocardial infarction in patients with atrial fibrillation: A nationwide population-based cohort study. <i>PLoS ONE</i> , 2020, 15, e0227571.	1.1	0
986	Clinical characteristics, management and outcomes of patients with acute coronary syndrome and atrial fibrillation: real-world data from two nationwide registries in Italy. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 99-105.	0.6	6
987	Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 555-568.	1.3	27
988	Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 1062.	1.0	2
989	Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1689-1713.	1.2	124
990	Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. <i>Lancet</i> , The, 2020, 395, 1374-1381.	6.3	205
991	Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-12.	1.1	5
992	Efficacy of Cangrelor as Bridging Therapy Post PCI. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020, 20, 227-231.	0.2	2
993	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008349.	1.4	15

#	ARTICLE	IF	CITATIONS
994	Long-term prognosis of <i>de novo</i> atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 189-195.	1.4	11
995	Aspirin-omitted dual antithrombotic therapy in non-valvular atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary intervention: results of a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 218-224.	1.4	12
996	Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs, 2021, 21, 11-20.	1.0	2
997	Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients. American Journal of Cardiovascular Drugs, 2021, 21, 21-34.	1.0	4
998	Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. Revista Espanola De Cardiologia (English Ed), 2021, 74, 140-148.	0.4	5
999	Prognostic significance of suboptimal secondary prevention pharmacotherapy after acute coronary syndromes. Internal Medicine Journal, 2021, 51, 366-374.	0.5	9
1000	The role of rivaroxaban for patients with atherosclerotic vascular disease in the modern era. Catheterization and Cardiovascular Interventions, 2021, 97, 1221-1229.	0.7	0
1001	Left ventricular thrombosis: new perspectives on an old problem. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 158-167.	1.4	50
1002	Pharmacology before, during and after percutaneous coronary intervention. Heart, 2021, 107, 585-592.	1.2	4
1003	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
1004	The 2020 European Society of Cardiology non-ST-segment elevation acute coronary syndromes guideline: the good, the bad and the ugly. Heart, 2021, 107, 444-446.	1.2	2
1005	Antithrombotic therapy for patients with chronic coronary syndromes. Heart, 2021, 107, 925-933.	1.2	11
1006	Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 581-588.	0.7	7
1007	Real World Prescribing Strategies for Patients With an Indication for Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 67-74.	1.0	0
1008	Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. Clinical Research in Cardiology, 2021, 110, 759-774.	1.5	6
1009	How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018. Netherlands Heart Journal, 2021, 29, 135-141.	0.3	4
1010	Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting. Journal of Cardiology, 2021, 77, 93-99.	0.8	0
1011	Left Atrial Appendage Closure Review: Addressing Unmet Needs of AF Mediated Stroke Prevention with Evolving Science. Structural Heart, 2021, 5, 3-10.	0.2	1

#	ARTICLE	IF	CITATIONS
1012	Comparison of effects of triple antithrombotic therapy and dual antiplatelet therapy on long-term outcomes of acute myocardial infarction. <i>Heart and Vessels</i> , 2021, 36, 345-358.	0.5	4
1013	Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21.	1.0	18
1014	2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 629-658.	1.2	144
1015	Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1546-1554.	2.3	1
1016	Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study. <i>Journal of Cardiology</i> , 2021, 77, 186-194.	0.8	4
1017	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	1.0	3,048
1018	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	1.0	5,583
1019	Antithrombotic Therapy and Outcomes of Patients With New-Onset Transient Atrial Fibrillation After ST-Segment Elevation Myocardial Infarction. <i>American Journal of Therapeutics</i> , 2021, 28, e30-e40.	0.5	2
1020	Efficacy and safety outcomes of short duration antiplatelet therapy with early cessation of aspirin post percutaneous coronary intervention: a systematic review and meta-analysis. <i>Current Cardiology Reviews</i> , 2021, 17, .	0.6	1
1022	Moving from dual antiplatelet therapy to monotherapy based on P2Y ₁₂ receptor blockade—why it could be a novel paradigm?. , 2021, , 167-191.		0
1023	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e018304.	1.6	9
1024	Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. <i>Thrombosis and Haemostasis</i> , 2021, 121, 854-866.	1.8	8
1025	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.3	9
1026	Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. <i>PLoS ONE</i> , 2021, 16, e0244723.	1.1	2
1028	Use of Direct Oral Anticoagulants After Percutaneous Coronary Intervention. , 2021, , 255-270.		0
1030	Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention. <i>Netherlands Heart Journal</i> , 2021, 29, 119-120.	0.3	0
1031	A predictive nomogram of bleeding risk in patients with atrial fibrillation after drug-eluting stent implantation. <i>Annals of Translational Medicine</i> , 2021, 9, 193-193.	0.7	1
1032	Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 164-169.	0.8	3

#	ARTICLE	IF	CITATIONS
1033	Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelinesâ€”data from the POLish Atrial Fibrillation (POL-AF) Registry. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 14-27.	0.7	8
1034	Tratamiento antiagregante de muy corta duraci3n tras la ICP y nuevos SLF: metan3lisis de 5 estudios aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 140-148.	0.6	14
1035	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	1.6	119
1036	Management of Antithrombotic Therapy after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2021, 384, 452-460.	13.9	66
1037	Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 875-876.	1.3	0
1039	Antithrombotic strategies in elderly patients with acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 232-245.	0.7	2
1040	Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. <i>Atherosclerosis</i> , 2021, 321, 39-44.	0.4	6
1041	Characteristics and antithrombotic treatment patterns of patients with concomitant coronary artery disease and atrial fibrillation from Thailandâ€™s COOL-AF registry. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 117.	0.7	2
1042	Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis. <i>Current Drug Targets</i> , 2021, 22, 399-419.	1.0	1
1043	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 1215-1223.	1.6	9
1044	Long term risk and costs of bleeding in men and women treated with triple antithrombotic therapyâ€”An observational study. <i>PLoS ONE</i> , 2021, 16, e0248359.	1.1	1
1045	Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1505.	1.0	4
1046	In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 221-227.	0.8	0
1047	Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105654.	0.7	5
1048	Outcomes of left ventricular thrombosis in post-acute myocardial infarction patients stratified by antithrombotic strategies: A meta-analysis with meta-regression. <i>International Journal of Cardiology</i> , 2021, 329, 36-45.	0.8	13
1049	Oral anticoagulation and outcomes in patients with acute myocardial infarction: Insights from the Hungarian Myocardial Infarction Registry. <i>International Journal of Clinical Practice</i> , 2021, 75, e14179.	0.8	1
1050	Antithrombotic Therapy Recommendations in the European Society of Cardiology Guidelines: How Robust Are the Randomized Controlled Trials Underpinning Them?. <i>TH Open</i> , 2021, 05, e125-e133.	0.7	1
1051	Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 501-507.	0.8	0

#	ARTICLE	IF	CITATIONS
1052	Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 424-426.	0.8	1
1053	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 768-780.	1.1	5
1054	Atrial Fibrillation and Ischemic Stroke: A Clinical Review. <i>Seminars in Neurology</i> , 2021, 41, 348-364.	0.5	37
1055	Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. <i>Seminars in Neurology</i> , 2021, 41, 365-387.	0.5	2
1056	Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 144, S32-S39.	0.7	2
1057	Antithrombotic Therapy With or Without Aspirin After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients Taking Oral Anticoagulation: A Meta-Analysis and Network Analysis of Randomized Controlled Trials. <i>Cardiovascular Revascularization Medicine</i> , 2022, 36, 99-106.	0.3	3
1058	Aspirin at 120: Retiring, recombining, or repurposing?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12516.	1.0	6
1059	Predictors of Anticoagulation Use in Indigenous and Non-Indigenous Australians With Atrial Fibrillation. <i>Heart Lung and Circulation</i> , 2021, 30, 707-713.	0.2	0
1060	Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation. <i>US Cardiology Review</i> , 0, 15, .	0.5	0
1061	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. <i>Advances in Therapy</i> , 2021, 38, 2891-2907.	1.3	7
1062	Antiplatelet Therapy And Percutaneous Coronary Interventions. <i>Current Cardiology Reviews</i> , 2021, 17, 232-243.	0.6	0
1063	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <i>Russian Journal of Cardiology</i> , 2021, 26, 4449.	0.4	63
1064	Comparing Endovascular Treatment Methods in Acute Ischemic Stroke Due to Tandem Occlusion Focusing on Clinical Aspects. <i>Life</i> , 2021, 11, 458.	1.1	2
1065	Characteristics and outcomes in patients with atrial fibrillation and acute coronary syndrome treated with ticagrelor and novel oral anticoagulants. <i>Thrombosis Update</i> , 2021, 3, 100054.	0.4	0
1066	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after <scp>PCI</scp> in patients with atrial fibrillation (a <scp>RE-DUAL) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Cardiology</i> , 2021, 44, 1002-1010.	0.7	2
1068	Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation. <i>Heart</i> , 2022, 108, 285-291.	1.2	8
1069	Efficacy and safety of rivaroxaban and ticagrelor in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Contemporary Clinical Trials</i> , 2021, 104, 106365.	0.8	2
1071	Single Antiplatelet Therapy With Prasugrel vs. Dual Antiplatelet Therapy in Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk. <i>Circulation Journal</i> , 2021, 85, 785-793.	0.7	8

#	ARTICLE	IF	CITATIONS
1072	Preliminary Study on the Safety and Efficacy of One-Stop Treatment of Percutaneous LAO Combined with Coronary Intervention for Higher Risk of Bleeding in Patients with AF Complicated with CHD. Heart Surgery Forum, 2021, 24, E474-E478.	0.2	1
1073	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 648-659.	1.4	11
1074	Prise en charge du syndrome coronaire aigu sans élévation du segment ST, nouvelles recommandations ESC 2020. Journal Européen Des Urgences Et De Réanimation, 2021, 33, 82-87.	0.1	0
1076	Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update. Frontiers in Cardiovascular Medicine, 2021, 8, 660986.	1.1	3
1077	Comparison of anticoagulated versus non-anticoagulated patients with intra-aortic balloon pumps. Thrombosis Journal, 2021, 19, 46.	0.9	4
1078	Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation. Deutsches Arzteblatt International, 2021, 118, .	0.6	2
1079	Baseline thrombocytopenia in acute coronary syndrome: The lower, the worse. International Journal of Cardiology, 2021, 332, 1-7.	0.8	3
1080	How to Manage the Perioperative Patient on Combined Anticoagulant and Antiplatelet Therapy: Comments on the 2020 ACC Consensus Decision Pathway. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1561-1564.	0.6	8
1081	Surgery for Coagulopathy-Related Intracerebral Hemorrhage: Craniotomy vs. Minimally Invasive Neurosurgery. Life, 2021, 11, 564.	1.1	1
1082	Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial. Journal of Clinical Medicine, 2021, 10, 2699.	1.0	11
1084	Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 625-629.	1.0	2
1085	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. CJC Open, 2021, 3, 1419-1427.	0.7	1
1086	Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention. Pharmacology, 2021, 106, 682-686.	0.9	1
1087	Aspirin versus P2Y ₁₂ inhibitors with anticoagulation therapy for atrial fibrillation. Heart, 2021, 107, 1731-1738.	1.2	2
1088	Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis. Atherothrombosis, 2021, , 89-105.	0.1	1
1089	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 181-264.	0.3	45
1090	What antithrombotic therapy should I use for my patient with atrial fibrillation who underwent percutaneous coronary intervention or had an acute coronary syndrome?. Cleveland Clinic Journal of Medicine, 2021, 88, 389-392.	0.6	1
1091	An update on antithrombotic therapy in atrial fibrillation patients in long-term ambulatory setting after percutaneous coronary intervention: where do we go from here?. Expert Opinion on Pharmacotherapy, 2021, 22, 2033-2051.	0.9	3

#	ARTICLE	IF	CITATIONS
1093	Dual Versus Triple Therapy in Patients with Acute Coronary Syndrome and an Anticoagulation Indication: A Systematic Review with Meta-Analysis and Trial-Sequential Analysis. <i>Cardiology in Review</i> , 2021, 29, 245-252.	0.6	1
1094	Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2021, 238, 89-99.	1.2	12
1095	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2022, 43, 561-632.	1.0	2,169
1096	Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 436-445.	1.0	8
1097	Apixaban versus Phenprocoumon: Oral Anticoagulation plus antiplatelet therapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF). <i>IJC Heart and Vasculature</i> , 2021, 35, 100810.	0.6	2
1098	2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical Settings. <i>Korean Journal of Medicine</i> , 2021, 96, 264-295.	0.1	0
1099	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. <i>Russian Journal of Cardiology</i> , 2021, 26, 4594.	0.4	89
1100	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	6.1	71
1101	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 727-800.	0.6	344
1102	Missed Opportunities to Initiate Oral Anticoagulant in Atrial Fibrillation: Insights from Australian Acute Coronary Syndrome Registries. <i>Heart Lung and Circulation</i> , 2021, 30, 1157-1165.	0.2	2
1103	Antithrombotic Treatment After Surgical and Transcatheter Heart Valve Repair and Replacement. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 702780.	1.1	10
1104	Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. <i>EuroIntervention</i> , 2021, 17, 474-480.	1.4	4
1105	Management of acute coronary syndromes in older adults. <i>European Heart Journal</i> , 2022, 43, 1542-1553.	1.0	24
1106	Rivaroxaban versus Vitamin K Antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction. <i>Heart and Vessels</i> , 2022, 37, 374-384.	0.5	14
1107	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1196-1211.	1.6	41
1108	Review of the 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation—What Has Changed and How Does This Affect Daily Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 3922.	1.0	5
1109	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111783.	2.5	0
1110	The bleeding risk treatment paradox at the physician and hospital level: Implications for reducing bleeding in patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2022, 243, 221-231.	1.2	2

#	ARTICLE	IF	CITATIONS
1111	Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 628-637.	0.3	0
1112	Antithrombotic strategies in elderly patients with atrial fibrillation revascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry. <i>International Journal of Cardiology</i> , 2021, 338, 63-71.	0.8	7
1113	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	1.6	4
1114	Treatment Pattern of Antithrombotic Therapy over Time after Percutaneous Coronary Intervention in Patients with Atrial Fibrillation in Real-World Practice in Korea. <i>Healthcare (Switzerland)</i> , 2021, 9, 1185.	1.0	0
1115	Newly Diagnosed Atrial Fibrillation in Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021, 10, e021417.	1.6	15
1116	Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model. <i>Circulation Reports</i> , 2021, 3, 504-510.	0.4	1
1117	Bleeding Risk Profile in Patients on Oral Anticoagulation Undergoing Percutaneous Coronary Interventions: A Prospective 24 Months Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 589426.	1.1	0
1118	Optimisation of oral anticoagulants for patients with atrial fibrillation within 12 months after percutaneous coronary intervention: A meta-analysis and systematic review. <i>IJC Heart and Vasculature</i> , 2021, 36, 100850.	0.6	2
1119	Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis. <i>American Heart Journal</i> , 2021, 242, 71-81.	1.2	0
1120	Secondary Prevention of Cardioembolic Stroke. , 2022, , 932-943.e4.		0
1121	The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it?. , 2021, , 193-199.		0
1122	Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Cardiology</i> , 2021, 146, 1-6.	0.6	0
1123	Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2021, 51, 409.	0.7	10
1125	From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach. <i>European Journal of Internal Medicine</i> , 2020, 77, 27-29.	1.0	2
1126	Incidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndrome. <i>International Journal of Cardiology</i> , 2019, 276, 20-25.	0.8	11
1127	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021, 42, 339-351.	1.0	57
1128	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk. <i>Current Opinion in Cardiology</i> , 2015, 30, 325-332.	0.8	8
1129	Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention; insights from a meta-analysis. <i>Coronary Artery Disease</i> , 2021, 32, 31-35.	0.3	4

#	ARTICLE	IF	CITATIONS
1130	The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2021, 32, 288-294.	0.3	3
1131	Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. <i>BMJ Open</i> , 2020, 10, e041044.	0.8	11
1132	Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis. <i>JCI Insight</i> , 2018, 3, .	2.3	23
1133	Dual versus single antiplatelet therapy for patients with long-term oral anticoagulation undergoing coronary intervention: a systematic review and meta-analysis. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 725-736.	0.2	2
1134	Is Female Sex Always a Risk for Bleeding?. <i>Circulation Journal</i> , 2018, 82, 1743-1745.	0.7	1
1135	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. <i>Circulation Journal</i> , 2019, 83, 1085-1196.	0.7	324
1136	Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk—A Prospective Cohort Study (PENDULUM mono Study) . <i>Circulation Journal</i> , 2020, 85, 27-36.	0.7	14
1137	Improved Cardiovascular Disease Outcomes in Older Adults. <i>F1000Research</i> , 2016, 5, 112.	0.8	21
1138	Triple Antithrombotic Therapy after Percutaneous Coronary Intervention (PCI) in Patients with Indication for Oral Anticoagulation: Data from a Single Center Registry. <i>PLoS ONE</i> , 2015, 10, e0140101.	1.1	10
1139	Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy. <i>PLoS ONE</i> , 2016, 11, e0157812.	1.1	6
1140	Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0186449.	1.1	10
1141	Is Aspirin Still the Cornerstone of Antiplatelet Therapy in Patients With Coronary Artery Disease? An Historical and Practical Narrative Review. <i>Hospital Practices and Research</i> , 2017, 2, 94-101.	0.1	5
1142	In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris. <i>Journal of Cardiovascular and Thoracic Research</i> , 2017, 9, 191-195.	0.3	4
1143	Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy. <i>European Cardiology Review</i> , 2020, 15, 1-8.	0.7	9
1144	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. <i>Russian Journal of Cardiology</i> , 2020, 25, 4103.	0.4	132
1146	Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. <i>Aging</i> , 2020, 12, 12930-12942.	1.4	1
1147	Bleeding in patients with atrial fibrillation treated with combined antiplatelet and anticoagulant therapy: time to turn the corner. <i>Annals of Translational Medicine</i> , 2019, 7, S198-S198.	0.7	5
1148	Ticagrelor or prasugrel vs. clopidogrel in combination with anticoagulation for treatment of acute coronary syndrome in patients with atrial fibrillation. <i>Annals of Translational Medicine</i> , 2019, 7, 406-406.	0.7	8

#	ARTICLE	IF	CITATIONS
1149	From WOEST to AUGUSTUS: a review of safety and efficacy of triple versus dual antithrombotic regimens in patients with atrial fibrillation requiring percutaneous coronary intervention for acute coronary syndrome. <i>Annals of Translational Medicine</i> , 2019, 7, 405-405.	0.7	8
1150	<p>Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation</p>. <i>Core Evidence</i> , 2020, Volume 15, 1-6.	4.7	3
1151	Antithrombotic therapy in patients with atrial fibrillation and percutaneous coronary intervention: what has changed in the guidelines in 2020?. <i>Atherothrombosis</i> , 2020, , 56-64.	0.1	1
1152	Use of DOACs in real-world challenging settings: a Delphi Consensus from Italian cardiologists. <i>Minerva Cardioangiologica</i> , 2019, 67, 361-373.	1.2	6
1153	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). <i>Eurasian Heart Journal</i> , 2020, , 4-77.	0.2	17
1154	2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation. <i>Korean Journal of Medicine</i> , 2018, 93, 87-109.	0.1	8
1156	Dual antiplatelet therapy for acute coronary syndromes: How long to continue?. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 675-688.	0.6	2
1157	Anticoagulation in patients with atrial fibrillation and coronary artery disease. <i>Heart Views</i> , 2020, 21, 32.	0.1	4
1158	Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2017, 12, 2058-2066.	1.4	32
1159	Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. <i>EuroIntervention</i> , 2018, 14, e418-e425.	1.4	21
1160	Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation. <i>EuroIntervention</i> , 2019, 15, 700-706.	1.4	5
1161	Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE-A study. <i>EuroIntervention</i> , 2020, 16, e164-e172.	1.4	10
1162	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2015, 10, 1015-1021.	1.4	21
1163	Omission of aspirin after ACS or stenting in patients with oral anticoagulation â€œ why have the goalposts moved?. <i>EuroIntervention</i> , 2019, 14, e1793-e1795.	1.4	5
1164	Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice?. <i>EuroIntervention</i> , 2018, 14, 19-23.	1.4	2
1165	Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. <i>EuroIntervention</i> , 2013, 9, 62-69.	1.4	66
1166	Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?. <i>EuroIntervention</i> , 2013, 9, S43-S47.	1.4	11
1167	Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. <i>EuroIntervention</i> , 2015, 11, 381-390.	1.4	38

#	ARTICLE	IF	CITATIONS
1168	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>EuroIntervention</i> , 2015, 10, 1095-1108.	1.4	29
1169	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2015, 10, 1024-1094.	1.4	251
1170	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019, 14, 1435-1534.	1.4	367
1171	Acute myocardial infarction, intraventricular thrombus and risk of systemic embolism. <i>Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia</i> , 2020, 164, 34-42.	0.2	4
1172	Post myocardial infarction and atrial fibrillation: Thromboprophylaxis and risk stratification using the CHA2DS2-VASc score. <i>Cardiology Journal</i> , 2014, 21, 451-453.	0.5	7
1175	Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 111-134.	0.3	4
1176	New-Onset Atrial Fibrillation in St-Segment Elevation Myocardial Infarction: Predictors and Impact on Therapy And Mortality. <i>Arquivos Brasileiros De Cardiologia</i> , 2019, 113, 948-957.	0.3	10
1177	The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, 75, 115-118.	0.4	0
1178	Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1013.	1.1	2
1179	Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease. <i>Hamostaseologie</i> , 2021, , .	0.9	0
1180	Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 751359.	1.1	2
1182	Triple Therapy: Risky but Sometimes Necessary. , 2014, , 185-212.		0
1183	Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 623-634.	0.3	7
1184	Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. , 2014, , 55-89.		0
1185	Recent advances in treatment of acute coronary syndromes. <i>F1000prime Reports</i> , 2013, 5, 56.	5.9	1
1186	Treatment of Intracranial Atherosclerotic Stenoses. , 2014, , 1-29.		0
1187	Oralna antikoagulantna terapija u elektivnim perkutanim koronarnim intervencijama. <i>Srce I Krvni Sudovi</i> , 2014, 33, 212-215.	0.1	0
1188	Optimizing Intensity and Duration of Oral Antithrombotic Therapy after Primary Percutaneous Coronary Intervention. , 2014, , 569-581.		0

#	ARTICLE	IF	CITATIONS
1190	Simultaneous Development of ST-Segment Elevation Myocardial Infarction and Pulmonary Embolism in an Healthy Elderly Woman. <i>Journal of the Korean Geriatrics Society</i> , 2014, 18, 251-255.	0.3	0
1191	Aggravation of coronary heart disease: the balance of risk and the risk of disease treatment. <i>Consilium Medicum</i> , 2015, 17, 30-35.	0.1	0
1192	Antithrombotic Treatment Strategy in Patients Who Underwent Coronary Stent Implantation. <i>Korean Journal of Medicine</i> , 2015, 88, 393.	0.1	0
1193	Periphere arterielle Verschlusskrankheit (pAVK): Revaskularisation, incl. Sekundärprophylaxe. , 2015, , 1-10.		0
1194	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015, 6, 267-277.	0.5	1
1195	Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation. <i>Interventional Cardiology Review</i> , 2015, 10, 139.	0.7	0
1196	Horizons in Novel Oral Anticoagulation Therapy in Concomitant Acute Coronary Syndromes and Atrial Fibrillation. <i>Cardiovascular Pharmacology: Open Access</i> , 2015, 04, .	0.1	0
1197	Treatment of Intracranial Atherosclerotic Stenoses. , 2015, , 2469-2495.		0
1198	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. , 2015, , 255-269.		0
1199	Percutaneous Coronary Intervention in Patients Who Have an Indication for Oral Anticoagulation – an Evidence-based Approach to Antithrombotic Therapy. <i>Interventional Cardiology Review</i> , 2015, 10, 16.	0.7	0
1200	Antithrombotic therapy in the anticoagulated patient undergoing percutaneous coronary intervention with coronary stenting. <i>Current Opinion in Cardiology</i> , 2015, 30, 319-324.	0.8	0
1201	Comparative Analysis of the Effects of Three Antithrombotic Regimens on Clinical Outcomes of Patients with Atrial Fibrillation and Recent Percutaneous Coronary Intervention with Stent. A Retrospective Cohort Study. <i>International Journal of Statistics in Medical Research</i> , 2015, 4, 260-269.	0.5	0
1202	Rimaining issues in antithrombotic therapy. <i>Journal of the Japanese Coronary Association</i> , 2016, 22, 45-50.	0.0	0
1203	Influence of Antithrombotic Agents on the Outcome at the Time of Hospital Discharge in Patients with Acute Intracerebral Hemorrhage. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and)</i> Tj ETQq1 1 0.784314 rBT /Overlo	0.8	0
1204	Overview of antiplatelet and anticoagulant therapy after acute myocardial infarction. <i>Intervencni A Akutni Kardiologie</i> , 2016, 15, 45-50.	0.0	0
1205	THE RESULTS OF MONITORING OF PATIENTS WITH PERSISTENT ARRHYTHMIAS AND CONDUCTION WITHIN 2 YEARS. <i>Russian Family Doctor</i> , 2016, 20, 43.	0.1	0
1207	Peri- and Post-procedural Antithrombotic Therapy in Women. , 2017, , 73-100.		1
1208	Left ventricular thrombosis can still complicate acute myocardial infarction. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, 819-826.	0.6	1

#	ARTICLE	IF	CITATIONS
1209	Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 19-38.		0
1210	Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 1-18.		0
1211	Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction. , 2017, , 95-120.		0
1212	Atrial Fibrillation on Vitamin K Antagonist Undergoing Urgent Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. , 2017, , 39-58.		0
1213	Atrial Fibrillation Early Complicating Acute Coronary Syndrome Treated with Percutaneous Coronary Intervention. , 2017, , 121-140.		0
1214	Background: Stroke Prevention in Patients with Atrial Fibrillation. , 2017, , 1-12.		0
1215	Oral Anticoagulant Therapy Post-Percutaneous Coronary Intervention. , 2017, , 173-179.		0
1216	Left Atrial Appendage Closure with Amplatzer Cardiac Plug in Nonvalvular Atrial Fibrillation: Safety and Long-Term Outcome. Arquivos Brasileiros De Cardiologia, 2017, 109, 541-549.	0.3	4
1217	Novedades en la evaluaci3n del riesgo hemorr3gico del paciente con cardiopat3a isqu3mica. Revista Espanola De Cardiologia Suplementos, 2017, 17, 16-23.	0.2	2
1218	Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cyclooxygenase inhibition. World Journal of Hematology, 2017, 6, 32.	0.1	4
1219	Antiplatelet and anticoagulant therapy in patients with coronary artery disease. Journal of the Japanese Coronary Association, 2017, 23, 117-119.	0.0	0
1220	Leitsymptom Thoraxschmerz. , 2017, , 1-67.		0
1221	VTE and Recent Drug Eluting Stent (DES) Placement. , 2017, , 135-141.		0
1222	Antiplatelet Therapy in Patients with Coronary Artery Disease. , 2017, , 1361-1371.		0
1223	Dileme oko primene dvojne antitrombocitne terapije kod bolesnika sa akutnim koronarnim sindromom i nakon perkutane oronarne intervencije. Srce I Krvni Sudovi, 2017, 36, 229-232.	0.1	0
1224	Platelet Inhibition as a Therapeutic Approach in Intravascular Intervention. Cardiac and Vascular Biology, 2017, , 99-109.	0.2	0
1225	6. Anticoagulant Therapy. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 238-245.	0.0	0
1226	Will PIONEER AF-PCI change my practice?. EuroIntervention, 2017, 13, e609-e612.	1.4	0

#	ARTICLE	IF	CITATIONS
1227	Additional Comments 1: Combination of Anti-thrombotic Drugs for Patients with Atrial Fibrillation and Coronary Artery Disease. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1863-1866.	0.0	0
1228	Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review. Current Cardiology Reviews, 2017, 13, 325-333.	0.6	0
1229	The Development of Antiplatelet Therapy after Percutaneous Coronary Intervention. International Physical Medicine & Rehabilitation Journal, 2017, 2, .	0.1	0
1230	Current consensus and future perspective of anti-thrombotic therapy for coronary artery disease. Journal of the Japanese Coronary Association, 2018, 24, 161-165.	0.0	0
1231	Non-ST-Segment Elevation Acute Coronary Syndromes (NSTE-ACS). , 2018, , 91-106.		0
1233	Percutaneous Coronary Intervention: Adjunctive Pharmacology. , 2018, , 161-180.		0
1234	Possibility of novel monitoring system for thrombus formation in patients with coronary artery disease. Journal of the Japanese Coronary Association, 2018, 24, 156-160.	0.0	0
1235	Periprocedural management of patients on anticoagulants and antiplatelet agents undergoing cardiac implantable electronic device implantation. In A Good Rythm, 2018, 1, 17-23.	0.0	0
1236	Update of antithrombotic treatment. Intervencni A Akutni Kardiologie, 2018, 17, 123-125.	0.0	0
1237	Triple therapy: worth the risk?. Minerva Medica, 2018, 109, 403-405.	0.3	1
1238	Antiplatelet Therapy in Cardiovascular Disease. , 2019, , 195-207.		0
1239	Intervenci3n coronaria en pacientes con fibrilaci3n auricular. Revista Espanola De Cardiologia Suplementos, 2019, 18, 15-20.	0.2	0
1240	Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation. European Journal of Arrhythmia & Electrophysiology, 2019, 5, 24.	0.2	0
1241	Conclusiones y recomendaciones pr3cticas. Revista Espanola De Cardiologia Suplementos, 2019, 18, 34-40.	0.2	0
1242	Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Journal of Lipid and Atherosclerosis, 2019, 8, 8.	1.1	0
1244	Fall 13" Die Hemikolektomie. , 2019, , 177-197.		0
1245	Kardiologische Aspekte bei intrakraniellen Blutungen (ICB). , 2019, , 71-85.		0
1246	A case of a patient with endovascular treatment after intravenous t-PA therapy for the acute cerebral infarction and acute myocardial infarction. Nosotchu, 2019, 41, 7-12.	0.0	2

#	ARTICLE	IF	CITATIONS
1248	Novel Oral Anticoagulants – Do Real-world Data Support our Expectations?. European Journal of Arrhythmia & Electrophysiology, 2019, 5, 48.	0.2	0
1249	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. Translational Medicine, 2019, 5, 10-22.	0.1	0
1250	2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants. Korean Journal of Medicine, 2019, 94, 57-82.	0.1	2
1251	VII. Strategy of Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 242-246.	0.0	0
1252	Triple Antithrombotic Therapy – Is It History or Should We Still Do It?. Journal of Interdisciplinary Medicine, 2019, 4, 7-10.	0.1	0
1253	Clopidogrel as a part of double disaggregant therapy in ACS: a reasonable choice in complex clinical situations. Meditsinskiy Sovet, 2019, , 20-29.	0.1	0
1254	Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI. Meditsinskiy Sovet, 2019, , 30-35.	0.1	0
1257	Antithrombotic therapy after percutaneous revascularization in patients on chronic oral anticoagulation treatment. REC: Interventional Cardiology, 2019, , .	0.0	4
1258	Triple Antithrombotic Therapy vs. Double Antithrombotic Therapy: One Scenario, 8 Questions, Many Conclusions. Current Cardiology Reviews, 2019, 15, 219-223.	0.6	0
1259	Trial Sequential Analysis Comparing Bleeding and Major Adverse Cardiovascular Events in Patients with Atrial Fibrillation and Acute Coronary Syndrome on Dual versus Triple Therapy. Cureus, 2019, 11, e4880.	0.2	1
1260	Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients with Coronary Heart Disease: A Meta-Analysis. Medical Science Monitor, 2019, 25, 5473-5481.	0.5	1
1261	Hit Two Birds With One Stone Via Thrombolytic Treatment. BalÄ±resir Medical Journal, 2019, 3, 85-89.	0.2	0
1262	Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention. Korean Journal of Medicine, 2019, 94, 330-342.	0.1	0
1263	Anticoagulation Patterns in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention in an Academic Center. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3785-3789.	0.2	0
1265	The Choice of Antithrombotic Therapy in a Patient with New-Onset Atrial Fibrillation and High Coronary Thrombotic risk.. Journal of Atrial Fibrillation, 2019, 12, 2184.	0.5	1
1266	Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Avicenna Journal of Medicine, 2019, 09, 123-128.	0.3	2
1267	Current management approaches to patients with atrial fibrillation and percutaneous coronary intervention. Medical Alphabet, 2019, 2, 12-17.	0.0	0
1268	Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention. Russian Journal of Cardiology, 2019, , 137-147.	0.4	0

#	ARTICLE	IF	CITATIONS
1269	Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. <i>Current Vascular Pharmacology</i> , 2019, 18, 92-99.	0.8	0
1270	Anticoagulation in Cardiac Patients. , 2020, , 77-102.		0
1271	Leitsymptom Thoraxschmerz. , 2020, , 1-71.		0
1272	Optimal Antithrombotic Therapy in Patients with Atrial Fibrillation During Percutaneous Coronary Intervention. <i>Doctor Ru</i> , 2020, 19, 6-13.	0.1	1
1273	Antithrombotic therapy in coronary artery disease patients complicated with atrial fibrillation. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2020, 31, 562-570.	0.1	0
1274	Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 69-81.	0.9	0
1275	TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention. <i>US Cardiology Review</i> , 0, 14, .	0.5	0
1276	The role of clopidogrel in the current treatment of acute coronary syndrome. <i>Atherothrombosis</i> , 2020, , 72-81.	0.1	0
1278	Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation. <i>Revista Da Associa�o M�dica Brasileira</i> , 2020, 66, 800-805.	0.3	1
1279	Efficacy and safety of direct oral anticoagulants and warfarin in atrial fibrillation patients as part of multicomponent antithrombotic therapy. <i>Kardiologicheskii Vestnik</i> , 2020, , 46-56.	0.1	1
1280	Defining the HBR patient â€“ another step in the right direction. <i>EuroIntervention</i> , 2020, 16, 357-360.	1.4	2
1281	Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 1024-1030.	0.3	1
1282	Dual Antithrombotic Therapy in Atrial Fibrillation Patients undergoing Percutaneous Coronary Angioplasty: The Impact of Bleeding Risk Score on Outcome. <i>Thrombosis and Haemostasis</i> , 2021, 121, 845-847.	1.8	0
1283	Development and validation of a prognostic prediction model for antithrombotic-related chronic subdural hematoma in patients with recent acute myocardial infarction. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1770-1784.	0.7	3
1284	HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. <i>Wiadomo�ci Lekarskie</i> , 2020, 73, 2528-2534.	0.1	1
1285	Safety and efficacy of dual versus triple antithrombotic therapy in Patients with atrial fibrillation undergoing percutaneous coronary intervention: A meta-analysis. <i>Avicenna Journal of Medicine</i> , 2020, 10, 232.	0.3	1
1286	Sex difference in clinical outcomes of Chinese patients with atrial fibrillation and coronary stenting according to age. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 17-23.	0.5	1
1287	Pharmacologic Management of Atrial Fibrillation and Flutter. <i>Contemporary Cardiology</i> , 2020, , 359-407.	0.0	0

#	ARTICLE	IF	CITATIONS
1288	Revised guidelines for anticoagulant therapy in patients with non-valvular atrial fibrillation. Japanese Journal of Thrombosis and Hemostasis, 2020, 31, 555-561.	0.1	0
1289	The prevalence of acute erosive-ulcerative gastroduodenal lesions in patients with cardiovascular diseases, taking anticoagulants and antiplatelet agents. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, , 65-74.	0.1	1
1290	Subanalysis of the AUGUSTUS trial. Russian Journal of Cardiology, 0, 25, 4104.	0.4	1
1291	Kontroverze - aspirin po PCI? Aspirin po PCI: proÄ•nepodÄ•ivat. Intervencni A Akutni Kardiologie, 2020, 19, 182-183.	0.0	0
1292	Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. Journal of Investigative Medicine, 2020, 68, 1317-1333.	0.7	0
1293	Stable Ischemic Heart Disease. , 2021, , 125-154.		0
1295	Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score. American Journal of Cardiovascular Disease, 2015, 5, 101-9.	0.5	0
1296	Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation. Journal of Atrial Fibrillation, 2015, 8, 1318.	0.5	5
1297	Triple antithrombotic therapy for atrial fibrillation and coronary stents. Canadian Family Physician, 2017, 63, 375-381.	0.1	4
1298	Impact of triple antithrombotic therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention in real-world practice. Journal of Geriatric Cardiology, 2017, 14, 679-687.	0.2	0
1299	Author`s Reply. Anatolian Journal of Cardiology, 2018, 19, 292.	0.5	0
1301	Comparative Effectiveness and Safety of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome or Percutaneous Coronary Intervention. Acta Cardiologica Sinica, 2019, 35, 508-521.	0.1	9
1302	A Brave New World. Acta Cardiologica Sinica, 2019, 35, 522-523.	0.1	0
1304	Is dual therapy the correct strategy in frail elderly patients with atrial fibrillation and acute coronary syndrome?. Journal of Geriatric Cardiology, 2020, 17, 51-57.	0.2	3
1305	Antithrombotic Strategies in Invasively Managed Patients with Non-ST Elevation Acute Coronary Syndromes and Non-Valvular Atrial Fibrillation in Romania. MÄ dica, 2021, 16, 6-15.	0.4	0
1306	Correspondence. Deutsches Ärztblatt International, 2021, 118, 739-740.	0.6	0
1307	Network Meta-analysis and Trial Sequential Analysis for Atrial Fibrillation Patients Receiving PCI or with ACS. Journal of the Chinese Medical Association, 2021, Publish Ahead of Print, .	0.6	0
1308	AntiagregaciÄn plaquetaria en monoterapia tras intervenciÄn coronaria percutÄnea: quÄ©, quiÄ©n, dÄnde, cuÄndo, por quÄ© y cÄmo. Revista Espanola De Cardiologia, 2022, 75, 115-118.	0.6	0

#	ARTICLE	IF	CITATIONS
1309	CHA ₂ DS ₂ -VASc score stratifies mortality risk in patients with and without atrial fibrillation. <i>Open Heart</i> , 2021, 8, e001794.	0.9	17
1310	Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. <i>PLoS ONE</i> , 2021, 16, e0259251.	1.1	2
1311	Carotid Artery Stenting in Patients with Atrial Fibrillation: Direct Oral Anticoagulants, Brief Double Antiplatelets, and Testing Strategy. <i>Journal of Clinical Medicine</i> , 2021, 10, 5242.	1.0	2
1312	Dual Antiplatelet Therapy after PCI: When Could We Go Shorter?. , 0, , .		0
1313	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021, 37, 1389-1426.	0.5	38
1314	2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary. <i>Thrombosis and Haemostasis</i> , 2022, 122, 020-047.	1.8	192
1315	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). <i>Eurasian Heart Journal</i> , 2021, , 6-59.	0.2	4
1316	Clpidogrel or ticagrelor alongside dabigatran in acute coronary syndrome and indication for NOAC: a study rationale. <i>Future Cardiology</i> , 2021, , .	0.5	1
1317	CHA ₂ DS ₂ -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2021, , e13717.	1.7	0
1318	Atrial fibrillation incidence, prevalence, predictors, and adverse outcomes in acute coronary syndromes: A pooled analysis of data from 8 million patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 414-422.	0.8	4
1319	The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials. <i>Scandinavian Cardiovascular Journal</i> , 2022, , 1-3.	0.4	0
1320	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2022, 79, e21-e129.	1.2	561
1321	AcetylsalicylsÄure: Heutiger Stellenwert in der antithrombotischen Therapie. , 0, , .		0
1322	Koronare Herzkrankheit: Aktuelle Aspekte der Behandlung. , 0, , .		0
1323	<i>Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1784-1789.	0.0	0
1324	Demographic, Clinical, and Angiographic Characteristics of Atrial Fibrillation Patients Suffering from de Novo Acute Myocardial Infarction: A Subgroup Analysis of the MINOCA-TR Study Population. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 20200468.	0.5	0
1325	Should we give triple therapy to patients with atrial fibrillation after percutaneous intervention?. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 599-601.	0.6	0
1327	Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 512.	1.0	3

#	ARTICLE	IF	CITATIONS
1328	JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. <i>Circulation Journal</i> , 2022, 86, 477-588.	0.7	38
1329	CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. <i>Cardiovascular Intervention and Therapeutics</i> , 2022, 37, 1-34.	1.2	62
1331	Gastrointestinal and Intracranial Bleeding Events After Second-Generation Drug-Eluting Stent Implantation—Their Association With High Bleeding Risk, Predictors, and Clinical Outcomes. <i>Circulation Journal</i> , 2022, 86, 775-783.	0.7	4
1333	Choice of antithrombotic therapy for patients with atrial fibrillation undergoing carotid angioplasty and stenting: a nationwide population-based study. <i>Scientific Reports</i> , 2022, 12, 1417.	1.6	3
1334	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, CIR0000000000001038.	1.6	177
1335	Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines. <i>Cureus</i> , 2022, 14, e21885.	0.2	8
1336	Triple Antithrombotic Therapy (Triple Therapy) After Percutaneous Coronary Intervention in Chronic Anticoagulation: A Literature Review. <i>Cureus</i> , 2022, 14, e21810.	0.2	5
1337	Is There a Role for Triple Therapy After ACS?. <i>Current Cardiology Reports</i> , 2022, 24, 191-200.	1.3	0
1338	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>EuroIntervention</i> , 2022, 17, e1126-e1196.	1.4	161
1339	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. <i>Journal of the American College of Cardiology</i> , 2022, 79, 417-427.	1.2	12
1340	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. <i>American Heart Journal</i> , 2022, 246, 32-43.	1.2	1
1341	One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients. <i>Journal of the American Heart Association</i> , 2022, 11, e023454.	1.6	7
1342	Use of Non-Vitamin K Dependent Oral Anticoagulant in Ischemic Stroke. <i>Journal of the Korean Neurological Association</i> , 2022, 40, 1-14.	0.0	1
1343	Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial. <i>American Heart Journal</i> , 2022, 247, 123-131.	1.2	3
1344	Bleeding risk score: limits and practicability. <i>Heart</i> , 2022, 108, 246-248.	1.2	1
1346	The feasibility and safety of "one-stop" left atrial appendage closure and percutaneous coronary intervention in atrial fibrillation patients with significant coronary artery disease (PCI-LAAC study). <i>American Journal of Cardiovascular Disease</i> , 2021, 11, 679-687.	0.5	0
1347	1. Anti-thrombotic Therapy for Acute and Chronic Coronary Syndrome. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 218-225.	0.0	0
1348	Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210746.	0.7	3

#	ARTICLE	IF	CITATIONS
1349	Advances in the treatment of ST Elevation Myocardial Infarction in the UK. JRSM Cardiovascular Disease, 2022, 11, 204800402210755.	0.4	2
1350	Impact of atrial fibrillation and the clinical outcomes in patients with acute myocardial infarction from the K-ACTIVE registry. Journal of Cardiology, 2022, 79, 768-775.	0.8	5
1351	When and How to Combine Antiplatelet and Anticoagulant Drugs?. Hamostaseologie, 2022, 42, 073-079.	0.9	7
1352	The WOESTÂ registry. Netherlands Heart Journal, 2022, , .	0.3	2
1353	Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary interventions. Complex Issues of Cardiovascular Diseases, 2022, 11, 98-106.	0.3	0
1354	<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973.	0.5	8
1355	Comparative Safety and Efficacy of Eight Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 2022, 9, 832164.	1.1	3
1356	Stratifying Bleeding Risk and Beyondâ€• Predicting Where Bleeding Will Occur â€•. Circulation Journal, 2022, , .	0.7	0
1357	Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study. Frontiers in Cardiovascular Medicine, 2022, 9, 846803.	1.1	2
1358	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2022, 86, 1790-1924.	0.7	49
1359	Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany. Herz, 2023, 48, 134-140.	0.4	4
1360	The optimal duration of triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. International Journal of Cardiology, 2022, 357, 33-38.	0.8	5
1361	Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. Cardiovascular Intervention and Therapeutics, 2022, 37, 255-263.	1.2	14
1362	Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome. International Journal of General Medicine, 2022, Volume 15, 2397-2414.	0.8	3
1363	Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients. Journal of Thrombosis and Thrombolysis, 2022, 54, 219-229.	1.0	4
1364	DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm. Current Atherosclerosis Reports, 2022, , .	2.0	0
1365	Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention, 2022, 17, e1371-e1396.	1.4	94
1366	The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Progress in Cardiovascular Diseases, 2021, 69, 11-17.	1.6	1

#	ARTICLE	IF	CITATIONS
1367	Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. Expert Review of Cardiovascular Therapy, 2021, 19, 1097-1117.	0.6	4
1368	Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial. BMJ Open, 2021, 11, e048354.	0.8	2
1370	Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis. American Heart Journal, 2022, 250, 1-10.	1.2	6
1371	Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation—Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries. Circulation Reports, 2022, 4, 194-204.	0.4	1
1376	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention, 2022, 18, e292-e302.	1.4	5
1377	Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study. EuroIntervention, 2022, 18, e303-e313.	1.4	2
1380	Concurrent coronary, left ventricle, and cerebral thrombosis—A trilogy. International Journal of Applied & Basic Medical Research, 2022, 12, 130.	0.2	1
1381	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. Frontiers in Pharmacology, 2022, 13, 878416.	1.6	2
1382	How to optimize treatment in patients with different forms of coronary artery disease. Meditsinskiy Sovet, 2022, , 273-279.	0.1	1
1383	P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding. Frontiers in Cardiovascular Medicine, 2022, 9, .	1.1	0
1386	Outcomes in elderly Chinese patients with atrial fibrillation and coronary artery disease. A report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (<sc>ChiOTEAF</sc>) registry. Journal of Arrhythmia, 2022, 38, 580-588.	0.5	2
1387	Drug Interactions Affecting Oral Anticoagulant Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	2.1	13
1388	ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes. European Heart Journal Supplements, 2022, 24, C254-C271.	0.0	2
1389	Adherence of patients with atrial fibrillation after acute coronary syndrome to antithrombotic therapy at stage III of cardiac rehabilitation: data from the local register of the Kirov region. Kardiologiya, 2022, 62, 27-32.	0.3	0
1390	Dual versus triple antithrombotic therapy for atrial fibrillation-ACS/PCI: One size does not fit all. Cardiovascular Revascularization Medicine, 2022, , .	0.3	0
1391	Management of antithrombotic therapy in patients at high bleeding risk after percutaneous coronary intervention for acute coronary syndromes: a case report. European Heart Journal - Case Reports, 2022, 6, .	0.3	0
1392	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
1393	Five-Year Impacts of Antithrombotic Therapy Based on 10-Year Clinical Outcomes of Cypher, Stent Implantation. Cardiology and Therapy, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1394	Comparative Effectiveness and Safety of Different Combinations of Antithrombotic Regimens in Atrial Fibrillation Patients With Stent Insertions. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 864-872.	2.3	0
1395	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
1396	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. <i>US Cardiology Review</i> , 0, 16, .	0.5	0
1397	Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillationâ€”The Fushimi AF Registry â€”. <i>Circulation Journal</i> , 2022, 86, 1252-1262.	0.7	2
1398	The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	0
1399	Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk. <i>Journal of Atherosclerosis and Thrombosis</i> , 2022, 29, 1409-1420.	0.9	11
1400	Clinical utility of the BIWACO score for patients with atrial fibrillation after percutaneous coronary intervention. <i>Heart and Vessels</i> , 0, , .	0.5	0
1401	Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention. <i>PLoS ONE</i> , 2022, 17, e0272140.	1.1	1
1402	Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. <i>European Heart Journal</i> , 2022, 43, 3512-3527.	1.0	16
1403	Massive Left Ventricular Thrombus Causing Bilateral Posterior Cerebral Artery Stroke: A Case Report and Review of Literature. <i>Cureus</i> , 2022, , .	0.2	0
1404	Epidemiology, Pathophysiology, and Management of Coronary Artery Disease in the Elderly. <i>International Journal of Angiology</i> , 2022, 31, 244-250.	0.2	2
1405	Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent. <i>Journal of Cardiovascular Medicine</i> , 0, Publish Ahead of Print, .	0.6	1
1406	Antithrombotic therapy after angioplasty of pulmonary vein stenosis due to atrial fibrillation ablation: A twoâ€”center experience and review of the literature. <i>Journal of Arrhythmia</i> , 0, , .	0.5	2
1407	Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 5605.	1.0	1
1408	Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry. <i>EuroIntervention</i> , 2022, 18, e656-e665.	1.4	0
1409	Antithrombotic Treatment and Its Association with Outcome in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 366.	0.8	2
1410	Oral anticoagulant therapy for patients with new-onset atrial fibrillation following acute myocardial infarction: A narrative review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
1411	Rivaroxaban in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention in Clinical Practice. <i>American Journal of Cardiology</i> , 2023, 189, 31-37.	0.7	1

#	ARTICLE	IF	CITATIONS
1412	Treatment of cerebral aneurysms with flow diversion or stent assisted coiling in patients on concurrent oral anticoagulation. <i>Neuroradiology Journal</i> , 0, , 197140092211144.	0.6	0
1413	Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 220-230.	1.4	7
1414	Combination of antiplatelet and anticoagulant therapy, component network meta-analysis of randomized controlled trials. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
1415	Analysis of Cerebrovascular Events after Coil Embolization of Unruptured Cerebral Aneurysms in Patients Taking Anticoagulants. <i>Journal of Neuroendovascular Therapy</i> , 2022, , .	0.1	0
1416	Acute Coronary Syndrome in the Older Adult Populations. <i>Contemporary Cardiology</i> , 2023, , 303-341.	0.0	0
1417	Long-term antithrombotic therapy after coronary artery bypass grafting in patients with preoperative atrial fibrillation. A nationwide observational study from the SWEDEHEART registry. <i>American Heart Journal</i> , 2023, 257, 69-77.	1.2	0
1418	The Woest Study: Is Now Time to Update the Recommendations Regarding the Antithrombotic Therapy in Patients with Indication for Oral Anticoagulation Undergoing Coronary Stent Implantation?. <i>European Medical Journal Interventional Cardiology</i> , 0, , 59-62.	0.0	0
1419	Controversies and challenges of coil embolization for intracranial aneurysm in a continuous-flow LVAD implanted patient: A case report. , 0, 14, 34.		0
1420	Hemostatic abnormalities associated with diabetes and their clinical implications. , 2023, , 199-220.		0
1421	Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 453-471.	0.9	5
1422	Anticoagulation for Left Ventricle Thrombus—Case Series and Literature Review for Use of Direct Oral Anticoagulants. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 41.	0.8	1
1423	Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis. <i>International Journal of Stroke</i> , 2023, 18, 812-820.	2.9	5
1424	Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome. <i>JAMA Network Open</i> , 2023, 6, e2255709.	2.8	3
1425	Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective. <i>Interventional Cardiology Review</i> , 0, 18, .	0.7	3
1426	Propensity-score-matched analysis of dual antiplatelet treatment and alternative antiplatelet regimens after transcatheter revascularizations. <i>Journal of Vascular Surgery</i> , 2023, 78, 142-149.	0.6	0
1427	Fabrication and characterization of polylactic acid nanobiocomposite scaffolds containing LDH and ZIF-8 drug carrier. , 2022, , .		0
1428	Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. , 2023, 2, 100607.		1
1429	Choice and Timing of Antithrombotic After Ischemic Stroke, Intracerebral Hemorrhage or Cerebral Venous Thrombosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, .	0.8	0

#	ARTICLE	IF	CITATIONS
1430	Spontaneous duodenal hematoma: a rare complication of triple antithrombotic therapy case report. <i>Future Cardiology</i> , 2023, 19, 71-76.	0.5	1
1431	Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF+PCI-II program. <i>Journal of Cardiology</i> , 2023, 82, 153-161.	0.8	1
1432	Efficacy and safety of rivaroxaban plus clopidogrel versus aspirin plus clopidogrel in patients with coronary atherosclerotic heart disease and gastrointestinal disease undergoing percutaneous coronary intervention: study protocol for a non-inferiority randomized controlled trial. <i>Trials</i> , 2023, 24, .	0.7	1
1433	Antithrombotics and Gastrointestinal Prophylaxis: A Systematic Review. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	0
1434	Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—A Translational Perspective. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6280.	1.8	1
1435	A Single-Center Bleeding Comparison of Warfarin Plus Aspirin or Clopidogrel Following Coronary Artery Bypass Grafting and Surgical Valve Replacement. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962311561.	0.7	0
1436	Arrhythmias After Acute Myocardial Infarction. <i>Yale Journal of Biology and Medicine</i> , 2023, 96, 83-94.	0.2	10
1438	An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions. <i>Clinical and Experimental Pharmacology and Physiology</i> , 0, .	0.9	0
1439	Cardiac Catheterization and Coronary Arteriography. , 2023, , 237-266.		0
1440	A network meta-analysis of the antithrombotic strategies in patients with atrial fibrillation and percutaneous coronary interventions: Focus on bleeding. <i>Hellenic Journal of Cardiology</i> , 2023, 73, 69-72.	0.4	1
1441	Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 311-328.	0.6	2
1445	Anticoagulation—Management for Mechanical Valves in the On-X Era. , 2023, , 383-407.		0
1454	Direct Oral Anticoagulants: Navigating Through Clinical Challenges. <i>Cardiovascular Drugs and Therapy</i> , 0, .	1.3	2